Dinesh Thakur

Safe and effective generic medications

Media

2021Address for Communication:

For media inquiries, please contact dinesh.thakur@gmail.com

Press Statements:

Statement by Dinesh Thakur Regarding US Government’s Case Against Ranbaxy (PDF)

Statement by Dinesh Thakur on admissions hearing at the Supreme Court of India (PDF)

Key Stories:

What really happened at Ranbaxy (Newslaundry.com, February 28, 2020)

Reality of Indian Pharma (Discussion in Hindi) (Lallantop, February 27, 2020)
Can we trust generic drugs (Accad & Koka Report, Podcast, November 20, 2019)
Pharma crusader Dinesh Thakur takes India’s drug regulators to court (Reuters; March 7, 2016)
Dirty medicine (Fortune Magazine; May 15, 2013)

In the News:

Making affordable generics more reliable (The Hindu, December 19, 2024)
Nearly 3000 drugs failed quality tests in FY 24, 282 were spurious (The Economic Times, December 5, 2024)
Painkillers, anti-infective drugs fail quality tests (Business Standard, December 2, 2024)
Drug regulator CDSCO flags 3 drugs as spurious, 56 not of standard quality (Business Standard, November 30, 2024)
Ban this carcinogenic heartburn drug (The Hindu, November 28, 2024)
How Telangana pharma firm falsified labels to export antibiotics to Russia (Southfirst, November 27, 2024)
Bad Medicine: Why India is racing to improve pharma standards amid US-China trade rivalry (CNA Insider, November 22, 2024)
Pharma experts demand urgent overhaul of drug regulation policy in India (O HeraldO, November 1, 2024)
Pharma, legal experts call for reforms in drug regulation (Times of India, October 29, 2024)
India has a substandard, fake drugs problem. Lack of recall law, scrutiny is making matters worse (The Print, October 9, 2024)
Pharma firms address drug regulator’s concerns over quality test failures (CNBC TV 18, October 1, 2024)
The Big Fight: Quality Control of Drugs (NDTV Profit, October 1, 2024)
Jan Vishwas Bill and the 53 NSQ drugs (The Public India, October 1, 2024)
Race to the bottom Podcast (Tradeoffs.org, September 24, 2024)
3 big threats to cheap, effective medicines that underpin US healthcare (Tradeoffs.org, September 24, 2024)
Transparency is the right drug for Ayush regulation (Hindustan Times, September 7, 2024)
Nearly 2000 drug plants are overdue for FDA checks after Covid delays, AP finds (The Associated Press, September 5, 2024)
5 takeaways from AP’s report on the big backlog of uninspected drug factories (The Associated Press, September 5, 2024)
Supreme Court pulled up Ayush Ministry over Rule 170 of the Drugs Act. Here is what it says (Indian Express, September 3, 2024)
Health Ministry bans FDCs every few years. Ask how they enter the market in the first place (The Print, August 30, 2024)
Anti-cancer injection, asthma drug, antibiotics & more: Medicines by top drug makers fail quality tests in July (News18, August 18, 2024)
Why fixed dose combination drugs need a tighter leash (The Hindu, August 12, 2024)
India to update rules to match global standards for medicines after flak over drugs (News18, July 30, 2024)
Introduce new law to tackle e-Phamacies (Deccan Herald, July 28,2024)
Why India has so many drugs with dangerously similar names (Global Health Now, July 11, 2024)
Generic Viagra safety called into doubt after false data found by the FDA (Bloomberg, July 9, 2024)
Trials, medical ethics and the orbit of power (The Hindu, July 4, 2024)
Paracetamol, 50 other drugs fail Quality Test. See full list (NDTV, June 27, 2024)
CDSCO finds 50 drugs manufactured in India to be of substandard quality (The Wire, June 24, 2024)
The toll of truth: What happens when you expose medical wrongdoing (Salon.com, June 21, 2024)
Pharmaceutical industry raises alarm over substitution of medicine at Jan Aushadhi Kendras (The Telegraph, June 17, 2024)
Maharashtra FDA Chief interview (The Indian Express, June 16, 2024)
Medical Whistleblowers like me have been humiliated, scorned and ostracized. No wonder so few of us have the courage to speak up (The Star, June 16, 2024)
Drug Action Network asks Health Minister to let Jan Aushadhi Kendras dispense generic substitutes of branded medication (The Hindu, June 15, 2024)
Alliance of India’s 26 top drug makers oppose generic drug substitution at Jan Aushadhi Kendras (The Print, May 31, 2024)
BHU’s Covaxin safety study: Cautious interpretation of results needed (The Wire, May 18, 2024)
Fact Check: Can Covaxin lead to death 2 years after vaccination (NDTV, May 17, 2024)
Why India struggles to keep its food safe (Deccan Herald, May 13, 2024)
Govt defends omission of rule restricting Ayurveda drug ads (Hindustan Times, May 7, 2024)
The absence of a quality mindset (Business Standard, May 7, 2024)
China can win without firing a single shot (Navbharat Times, May 6, 2024)
Every Vaccine carries a risk. If the benefits outweight it, you use it: Shahid Jameel (Economic Times, May 5, 2024)
Report on rare adverse side effects of Covidshield causes panic. But should it? (The Wire, May 5, 2024)
Major Indian drug makers Cipla, Glenmark, recall products from the US market over manufacturing lapses (The North Lines, May 5, 2024)
Why implementing drug regulation policies are still a challenge in India (The Week, May 5, 2024)
Unscientific Temper (The Telegraph, May 4, 2024)
Covidshield under scanner. Is Covaxin safe? (Times of India, May 3, 2024)
Panel to reform drug pricing authority packed with industry representatives (Times of India, May 3, 2024)
Covidshield’s rare side effects: In election season, dangers of politicizing vaccine (Indian Express, May 2, 2024)
Decades late, these set of basic rules for Indian Pharma can save lives (Economic Times, May 1, 2024)
477 Pune pharmaceutical stores found operational without pharmacists after FDA inspection (Pune Pulse, April 30, 2024)
Record US drug shortage a positive for Indian Pharma companies (Business Today, April 30, 2024)
Drug firms told to set up system for prompt recalls (Economic Times, April 30, 2024)
Indian state suspends licenses of 14 product of yoga guru in latest setback (Reuters, April 29, 2024)
Patanjali Saga: Ayush Ministry issues warning on misleading ads to traditional drugmakers (Business Today, April 27, 2024)
20 Drugs made in HP pharma firms failed testing in March (Times of India, April 27, 2024)
Panel to finalize list of over-the-counter drugs for sale at general stores (Economic Times, April 22, 2024)
US FDA pulls Natco Pharma for several violations at their Telangana plant (Business Standard, April 21, 2024)
Regulator issues distribution guidelines to ensure no substandard pharma products in market (The Print, April 18, 2024)
FDA slams three Indian drug makers in a flurry of recent form 483s (Fierce Pharma, April 16, 2024)
FDA lambasts Kilitch for unsanitary manufacturing conditions and issues warning letter to Natco (Fierce Pharma, April 10, 2024)
Cartelization of pharma trade bodies (The Hindu, April 10, 2024)
Drug recall still voluntary, experts express concern (Hindustan Times, April 8, 2024)
What if you consumed expired medicines, just a month late (India Today, April 8, 2024)
Dangerous game:On Patanjali’s Ayurved claims (The Hindu, April 4, 2024)
Himachal Pradesh probes 1680 failed drug samples in Baddi (Hindu Business Line, March 29, 2024)
India pharma quality lapses force US to look to China for lifesaving drugs (Nikkei Asia, March 22,2024)
Seven firms that failed drug quality tests gave money to political parties through electoral bonds (Scroll.in, March 18, 2024)
Fake Cancer drug case: 4 more employees of Delhi, Gurgaon hospitals arrested (Indian Express, March 16, 2024)
7 arrested for manufacture, sale of “life-saving” cancer drugs in Delhi: Here’s how the gang operated (Indian Express, March 13, 2024)
Why India needs a regulatory pathway for biosimilars? (Scroll.in, March 7, 2024)
33 drug samples of 21 Pharma Companies in Rajasthan fail testing (Zee Rajasthan, March 6, 2024)
Uzbekistan: Deadly cough syrup trial ends with lengthy convictions (Eurasianet, February 27,2024)
Several small pharma units told to halt operations over quality (Economic Times, February 23, 2024)
Licenses of 64 pharma companies canceled after government crackdown (The Hindu, February 19, 2024)
Drug regulator tightens sampling norms to test quality of medicines (The Print, February 17, 2024)
NHRC issues notice to Health Ministry, DCGI over drugs’ brand name issue: seeks response in 4 weeks (Deccan Herald, February 12, 2024)
Rx Dose of Quality Control Meds (The Economic Times, February 10, 2024)
Swiss and Indian pharma giants locked in big war; land at DCGI’s door over breast cancer drug (News18.com, February 9, 2024)
India’s problem: different drugs, identical brand names (The Hindu, January 25, 2024)
“The response defies belief”: Year of inaction leaves children at risk from bad cancer drugs (STATNews, January 25, 2024)
Nigeria tightens rules on Indian pharma exports, new standards may spark industry concerns (News18.com, January 17, 2024)
AAP government procured drugs from two blacklisted pharma firms with many failed quality tests (Newslaundry, January 17, 2024)
The story of a drug that India has failed to ban (Scroll.in, January 3, 2024)
Uttarakhand drug regulator enforces ban on cough syrup production without testing for toxic chemicals (News18.com, December 26, 2023)
India probe into bribery claim in toxic syrup tests nears completion (Reuters, December 21, 2023)
How tainted chemo wound up in Pediatric Cancer wards (Bloomberg Businessweek, December 15, 2023)
The threat of tainted cancer drugs (Bloomberg Businessweek, December 15, 2023)
CDSCO uncovers data manipulation, SOP violations by public testing labs (Economic Times, December 15, 2023)
India’s medicine regulator is criticized for quality checking only cough medicines destined for export (BMJ, December 14, 2023)
Union chemicals and fertilizer ministry says 303 of 504 central drug inspector posts vacant (The Telegraph, December 10, 2023)
India’s alarming “fixed dose combination” problem (The Hindu, December 8, 2023)
Complaint to PMO on medicine ads: Doctor cries inaction on misleading claims (The Telegraph, December 8, 2023)
The business of bad medicine (Bloomberg, December 5, 2023)
Over 50 cough syrup makers fail quality tests (Economic Times, December 3, 2023)
Pill Pain: India’s weak, convoluted and inefficient regulatory structure for FDCs (The Telegraph, December 1, 2023)
65% of MSME firms found manufacturing substandard drugs since Dec (Business Standard, November 30, 2023)
Getting pharma regulation right should be top priority (The Tribune, November 29, 2023)
Indian drug manufacturers benefit from Big Pharma interest beyond China (Reuters, November 26, 2023)
China-made Gelatin in Indian Medicines sparks regulatory clampdown on poor quality material (News18, November 25, 2023)
Modi Govt plans to use videography, Latest Digital solutions during raids at pharma firms (News18, November 25, 2023)
Drug regulator halts production at 76 units over poor standards (Economic Times, November 23, 2023)
India wide inspections of Pharma firms exposed major lapses in drug manufacturing, shows Govt analysis (News18.com, November 23, 2023)
Gambia parents ‘fight for children’ in landmark trial on India syrup deaths (Al Jazeera, November 20, 2023)
India must save the reputation of its Pharma industry (Business Standard, November 16, 2023)
Tainted Walmart, CVS eyedrops tied to unsanitary Indian factory (Bloomberg, November 10, 2023)
Shortcast of Coffee Podcast (November 8, 2023)
Boss of Indonesia cough syrup maker jailed after child deaths (BBC, November 2, 2023)
Two labs in India take on bulk testing for cough syrup samples for export (The Hindu, October 17, 2023)
Pharmacy: Heal Thyself – Kasauli Literature Fest (YouTube, October 14, 2023)
UP Govt allows cough syrup company linked to Uzbek deaths to re-open factory (Business Today, October 11, 2023)
Silencing of the LiverDoc and the dangerous anti-science trend in India today (Indian Express, October 10, 2023)
Improving drug procurement through a contract life-cycle approach (XDR, October 10, 2023)
Drug contamination crisis:Indian Pharma industry faces regulatory crackdown (CNBC TV18, October 9, 2023)
RSS’s pharma body writes to Health Ministry criticizing risk based inspections, backtracks later (News18, July 18, 2023)
Inspections resembling raids: RSS affiliate urges Govt to avoid “minor lapses” in Pharma firms (The Wire, October 7, 2023)
Diabeties drug among 48 to fail quality test (The Mint, October 5, 2023)
From Flawed data entries to no pest control and more: Inside details of probe into Kala-Amb based pharma firm (News18, October 5, 2023)
India declares two syrups from Norris Medicines as toxic after reports of poisoning deaths (WION, October 5, 2023)
India finds two more toxic cough syrups months after poisoning deaths (Reuters, October 4, 2023)
India manufactured syrups for cough, allergic rhinitis contamined with toxic levels of chemicals: CDSCO (Indian Express, October 4, 2023)
No unnecessary roaming – CDSCO is a sensitive office: Regulates visitors’ entry with immediate effect (News18, September 30, 2023)
Cough syrup killed scores of children. Why no one has been held to account (Reuters, September 14, 2023)
Equal access to safe medicines is a Global Human Right (NY Times, September 11, 2023)
The curious case of a “killer” drug with contradictory toxin test results at different government labs (The Wire, September 9, 2023)
How can we maintain the success of existing anti-microbials? (Chemistry World, September 4, 2023)
Jammu: Long wait for justice after India cough syrup deaths (BBC, September 3, 2023)
The right medicine: A uniform drug licensing scheme is sorely needed to overcome drug quality issues (Financial Express, September 18, 2023)
Why the FDA took so long to tackle a disputed cold remedy (NY Times, September 18, 2023)
Unsafe interventions (The Telegraph, September 17, 2023)
Cough syrup killed scores of children. Why no one has been held to account (Reuters, September 14, 2023)
Equal access to safe medicines is a Global Human Right (NY Times, September 11, 2023)
The curious case of a “killer” drug with contradictory toxin test results at different government labs (The Wire, September 9, 2023)
How can we maintain the success of existing anti-microbials? (Chemistry World, September 4, 2023)
Jammu: Long wait for justice after India cough syrup deaths (BBC, September 3, 2023)
I accept inferior drugs were bought to Lanka (The Sunday Times, September 3, 2023)
Patient safety or affordability: What should India prioritize? (Deccan Herald, September 2, 2023)
Drug regulator to closely monitor small drug firms (The Mint, September 1, 2023)
Whatever happened to the case of 66 child deaths linked to cough syrups from India ? (NPR, August 31, 2023)
Decoded:How India makes affordable drugs for the developed world, but deadly medicines for developing countries (Economic Times, August 31, 2023)
Carry on, Doctor (The New Indian Express, August 27, 2023)
Doctors in India raise concerns about new mandate to prescribe generic drugs (BMJ, August 22, 2023)
Maiden Pharmaceuticals:Fury in The Gambia over India cough syrup deaths (BBC, August 21, 2023)
Why India isnt ready for Generic Prescriptions yet (Manorama, August 20, 2023)
Jan Vishwas Bill: Harms common people, profits for the industry? (Lallantop, August 19, 2023)
Affordability is tied to quality (Express Pharma, August 18, 2023)
NDTV Jan Vishwas Act Debate: Viewers should know if panelists have a conflict of interest (Newslaundry, August 17, 2023)
Uzbekistan says contaminated Indian cough syrup was on the market due to bribery (Reuters, Aug 16, 2023)
A mysterious drug resistance threatens to undo gains made by TB patients (Scroll.in, August 17, 2023)
Hum Log: Why has the WHO issued alert for a product made by Indian pharma company (NDTV India, August 15, 2023)
Why doctors are protesting rule to prescribe generic drugs (Indian Express, August 15, 2023)
A dose of danger: Spurious supplements harm consumers (Deccan Herald, August 15, 2023)
If Govt action was enough, why is the WHO still flagging India made medicines? Asks Expert (NDTV, August 13, 2023)
Jan Vishwas Bill and its impact on healthcare (Herald Goa, August 11, 2023)
Enforcement of drug regulations is Lax (The Tribune, August 10, 2023)
To protect its image in pharmacy world, India should shut firms who dont comply (News18.com, August 7, 2023)
World’s largest abortion pill maker has a dark India link it might not be able to shake (Economic Tines, August 4, 2023)
Jan Vishwas Bill: A prescription for disaster (National Herald, August 4, 2023)
Industry, patient groups want draft drugs and medical devices bill recalled (Business Standard, August 4, 2023)
Freedom from Jail in 180 crimes, Jan Vishwas Bill changes laws (Jhakas Khabar, August 4, 2023)
India finds “violations” at a cough syrup maker linked to deaths in Cameroon (Reuters, August 4, 2023)
Jan Vishwas Bill: Will manufacturers of substandard drugs get away with just a fine? (Indian Express, August 4, 2023)
Why does India have a substandard drug problem ? (The Hindu Podcast, August 3, 2023)
Bill to ease penalties for low quality drugs passed in the parliament (Hindustan Times, August 3, 2023)
Jan Vishwas Bill, passed recently, further weakens regulation of pharmacies, experts say (Newsclick, August 3, 2023)
The Jan Vishwas Bill passed by Lok Sabha further dilutes regulation of pharmacies (Scroll.in, August 2, 2023)
India finds string of deficiencies among drug makers after risk tests (ET Health, August 2, 2023)
Jan Vishwas Bill passed by Rajya Sabha, experts raise red flag (CNBC TV18, August 2, 2023)
Global abortion pill provider buys from manufacturer with shoddy quality record (Bloomberg, August 1, 2023)
Modi’s Jan Vishwas Bill gives the pharmaceutical industry a get-out-of-jail card (Newlaundry, August 1,2023)
Jan Vishwas Bill- All you need to know ( News 9, August 1, 2o23)
Jan Vishwas Bill: No Jail term, only fines for drugs manufactured in violation of norms (CNBC-TV18, August 1, 2023)
Editorial: Short of expectations (Telangana Today, July 31, 2023)
A critical lapse in Jan Vishwas Bill (Business Standard, July 31, 2023)
Generic 2: Calls for Regulatory Vigilance (Business Standard, July 31, 2023)
My take – Dinesh Thakur: Deal between Govt and industry puts patients at risk (The Public India, July 30, 2023)
Jan Vishwas Bill: Changes to Drugs and Cosmetics Act trigger debate over punishment for substandard medicines (Indian Express, July 29, 2023)
“Weakened” Drugs and Cosmetics Act raises alarm among health experts (The New Indian Express, July 29, 2023)
Medicine convicts can stay out of jail by paying fine, says Union Health Ministry (The Telegraph, July 29. 2023)
Jan Vishwas Bill passed amid ruckus on Manipur: Threat to lives for ease of doing business (The Public India, July 29, 2023)
Questions raised about quality of cough syrup, why are rules not enforced? (NDTV, July 28, 2023)
How does the Jan Vishwas Bill dilute enforcement of D&C Act? (NDTV, July 28, 2023)
Indian made cough syrup sent to Iraq contains poison, test show (Bloomberg, July 28, 2023)
Fake British cough syrup linked to Cameroon child deaths was made in India, officials say (The Telegraph, July 28, 2023)
India made cold syrup sent to Iraq tainted with toxic chemicals, shows test (Business Standard, July 28, 2023)
Indian cough syrup sent to Iraq contains poison, test show (The Mint, July 28, 2023)
Jan Vishwas Bill doesnt dilute punitive provisions of the Drugs and Cosmetics Act, says health ministry (The Print, July 28, 2023)
Sri Lanka stops buying eye drops made in Gujarat after infections, vision loss (Scroll.in, July 28, 2023)
Modi Govt likely to bring in stricter pan-India system to recall substandard drugs from the market (The Print, July 26, 2023)
Biosimilars need to be regulated better (Deccan Herald, July 26, 2023)
‘Sue Indian Govt., Maiden Pharma, Importer in Cough Syrups case’: Gambian Presidential Task Force (The Wire, July 23, 2023)
48 drug samples, including Alkem’s PAN 40, Cadilla’s ACILOC 50 fail to qualify CDSCO test (medicaldialogues.in, July 22, 2023)
India mustn’t take shortcuts for making biosimilars, confusing affordability with efficacy is a bad idea (News18.com, July 17,2023)
Govt stops production of drugs at 31 firms over quality norms (Economic Times, July 13, 2023)
A WHO alert about an Indian pharma firm failed to spark strong regulatory action, experts say (Scroll.in, July 13, 2023)
Poisoned cough syrup killed kids. Authorities cut the investigation short (Bloomberg, July 11,2023)
Poisoned cough syrup traced to India reveals lapses in regulation (Business Standard, July 11, 2023)
Undercover Asia: Tainted Medicine Scandal (Undercover Asia, July 10, 2023)
Govt tightens screws on pharma MSMEs, stresses on good manufacturing practices, self regulation (The Print, 11 July 2023)
Drug quality concerns take center stage at pharma export council’s global meet (Moneycontrol.com, July 08. 2023)
Make the drug approval files publicly accessible (Hindustan Times, July 7, 2023)
Tackling quality concerns in Indian drug exports (BQPrime, July 6, 2023)
‘Probes bought bad name to Indian drug makers: RSS-affiliated MSME lobby writes to Health Ministry, then retracts ( News18, July 6, 2023)
Central drug authority to rationalize regulations (The Hindu, July 6, 2023)
Several immunizations drives hit, Union Govt prods Bharat Biotech over delays in vaccine supplies (The Print, July 6, 2023)
In search of consistent quality (Express Pharma, July 3, 2023)
Italian hospitals imported unapproved, substandard cancer drug (The Bureau of Investigative Journalism, June 29, 2023)
What is the truth behind made in India cough syrups which are linked to deaths of several children? (Lallantop, June 21, 2023)
2 more Indian drug makers under lens in Nigeria for contamination (Business Standard, June 19, 2023)
More problems found at Indian pharma company causing cancer drug shortage (Bloomberg, June 15, 2023)
A WHO alert about Indian pharma firm failed to spark strong regulatory action, experts say (Scroll.in, June 13, 2023)
India probes bribery claim in toxic syrup case (Economic Times, June 13, 2023)
India probes bribery claims in toxic syrup tests (Reuters, June 13, 2023)
Solan: No stern laws, fake drug makers misusing industrial plots (The Tribune, June 13, 2023)
India needs to restore faith in “World’s Pharmacy” (Bloomberg, June 12, 2023)
India needs to restore faith in “World’s Pharmacy” (Economic Times, June 12, 2023)
US military is so worried about drug safety, it wants to test widely used medicines (Bloomberg, June 7, 2023)
US FDA uncovers failures in Indian pharma factories (Deccan Herald, June 7, 2023)
Spare the rod, change the law (The Hindu, June 6, 2023)
Intas pharma Ahmedabad facility gets import alert from US FDA (Forbes India, June 5, 2023)
US watchdog cracks down on Indian drug makers (Bloomberg, June 5, 2023)
India bans 14 fixed dose medicines for likely posing risks to health (Economic Times, June 4, 2023)
The Gambia hires US lawyers over syrup scandal (BBC, June 2, 2023)
Is India doing enough to clean up its pharmaceutical industry (DW, June 02, 2023)
Gambia hires US law firm to consider action on toxic Indian cough syrups (Pharmalive, June 1, 2023)
Center probes Gujarat Pharma firm over its eyedrops being linked to vision damage cases in Sri Lanka (News18. June 1, 2023)
Contaminated drugs, shredded papers: US FDA uncovers Failures in Indian pharma factories (Bloomberg, May 31, 2023)
Lax fear on misleading traditional medicine advertisements, finger on Center (The Telegraph, May 27, 2023)
Substandard drug manufacturing: Himachal Pradesh High Court seeks status of testing labs (Livelaw, May 26, 2023)
Indian drugs led to child deaths in The Gambia: Panel (Economic Times, May 24, 2023)
Global Experts’ Causality Assessment confirms Indian cough syrups led to child deaths in the Gambia (The Wire, May 24, 2023)
We dont pay enough for drugs (Bloomberg, May 24, 2023)
Haryana blacklists Maiden Pharma, but no penal action (The Tribune, May 23, 2023)
Des médicaments indiens qui rendent malade (La Presse, May 21, 2023)
How India’s drug regulatory regime can ensure greater credibility for our pharma industry (Indian Express, May 18, 2023)
India considers policy change after cough syrup deaths (Reuters, May 18, 2023)
The US needs to pressure India to improve drug safety (StatNews, May 16, 2023)
India’s ‘pharmacy of the world’ moniker is under threat. Here’s why (Forbes India, May 15, 2023)
India’s evolving pharmaceutical industry needs stringent scrutiny (Greater Kashmir, May 11, 2023)
Why are FDA inspections so ineffective and disappointing? (People’s Pharmacy, May 8, 2023)
Why does India not have a law to recall bad quality drugs from the market (The Hindu, May 5, 2023)
Table talk with Jo: Indian pharma and its dangerous trail (YouTube, May 5, 2023)
Indian cough syrup: mystery middleman may be clue (Reuters, May 1, 2023)
Regulating India’s Generic Drugs is a life or death problem for Africa (Devex, April 21, 2023)
Sri Lanka suspends use of Indian eye drops (Newsfirst, April 20, 2023)
Inside the online market for overseas abortion pills (NY Times, April 13, 2023)
India’s drug industry needs a major overhaul (Economic Times, April 5, 2023)
Just how dangerous are India’s generic drugs? Very (Washington Post, April 5,2023)
Just how dangerous are India’s generic drugs? Very (BQ Prime, April 5, 2023)
Drug resistant bacteria tied to eye-drops can spread person to person (NY Times, April 3, 2023)
7 Baddi pharma units face “stop manufacturing” order after inspection (The Tribune, March 29, 2023)
“Spurious Drugs” Center cracks down on 18 firms (Hindustan Times, March 29, 2023)
Dont Dilute the Drugs and Cosmetics Act (Economic Times, March 29, 2023)
Licenses of 18 pharma firms cancelled in crackdown (Indian Express, March 29, 2023)
Govt cancels licenses of 18 pharma companies allegedly manufacturing spurious drugs (The Mint, March 29, 2023)
India’s pharma sector has an export problem, here’s where the challenges lie (BT Mag, April 2, 2023)
Low quality drugs are posing a risk to India’s image. Can Rajeev Raghuvanshi fix the faults? (Economic Times, March 29, 2023)
WHO warns contaminated batches of Indian manufactured medication circulating in Lebanon and Yemen (The Telegraph, March 28, 2023)
India’s pharma sector has an export problem, here’s where the challenges lie (BT Mag, April 2, 2023)
FDA and WHO investigate contaminated cough syrup from India linked to 300 deaths (MDLinx, March 28, 2023)
Children are dying. We need a worldwide medicines treaty to avoid further tragedies (The Guardian, March 23, 2023)
Regulatory body cancels Marion Biotech’s license (Hindustan Times, March 23, 2023)
PGI Propofol deaths: 6 months later, no one held responsible (Times of India, March 22, 2023)
Outbreak of extensively drug resistant pseudomonas aeruginosa associated with artificial tears (US CDC, March 21, 2023)
Explained: What is plaguing drug regulation in India? (Facts Cresendo, March 25, 2023)
Govt plans common drugs standards for all state drug regulators (Hindustan Times, March 17, 2023)
Editorial: Standardize Drug Regulation (Telangana Today, March 20, 2023)
Towards a more robust model of drug regulation (Hindustan Times Editorial, March 17, 2023)
Center should regulate manufacture of drugs instead of state bodies, new bill moots (Economic Times, March 12, 2023)
Doublespeak on Drug Regulation must stop (The Tribune, March 11, 2023)
Gambian child deaths fuel alarm over rules in “world’s biggest pharmacy” India (Financial Times, March 11, 2023)
As African children died, doctors fought to get Indian cough syrup banned (Reuters, March 10, 2023)
The mystery of deadly poisoned cough syrup (The Telegraph, March 8, 2023)
Licenses of six cough syrup makers in Maharashtra suspended for violation of rules (The Hindu, March 4, 2023)
Book Review: Shocking study on drug regulation leaves us wiser (Deccan Chronicle, February 25, 2023)
The Bittersweet Pill (Medium, February 25, 2023)
The horror story of drug regulation in India (The Newsminute, February 20, 2023)
Regulating new drugs in India needs to be improved (The Lancet, February 17, 2023)
First it was blood pressure medication. Now FDA eyes more drugs for cancer causing chemicals (USA Today, February 16, 2023)
Contaminated cough syrups’ death toll passes 300 in four months (Chemistry World, February 14, 2023)
Are medicines making our healthcare better or worse? (Newslaundry Hindi, February 14, 2023)
Ayurveda:Regulation of this alternate system of medicine is urgently needed on many fronts (DowntoEarth, February 14, 2023)
Book Review: ‘Bottle of Lies’ exposes black sheep of India Pharma (The Outlook, February 13, 2023)
The contaminated syrup tragedy in Jammu and Kashmir’s Ramnagar (Outlook India, February 12, 2023)
The Crisis of Drug Quality in India (Bangalore International Center, February 9, 2023)
Drug regulators in India must do better oversight (Deccan Chronicle, February 9. 2023)
Bharat Biotech’s Krishna Ella suggests merging state drug regulators with the central body to ensure ‘one quality one standard’ (The Hindu, February 5, 2023)
Are Indian drugs safe? (IVM Podcasts, February 3, 2023)
Book review: How rotten is drug regulation in India? (BMJ Global Health, February 1, 2023)
Is Drug Regulation in India a myth? (The Diplomat, February 1, 2023)
Tainted drug deaths, weak regulation corrode confidence in Indian drugs (CIDRAP, January 28, 2023)
A strong dose (Frontline Magazine, January 26, 2023)
The drug was meant to save children’s lives:Instead, they are dying (The Bureau of Investigative Journalism, January 25, 2023)
Inside India’s shadowy pharma industry – dingy drug units, cash payments, poor inspections (The Print, January 24, 2023)
WHO investigating links between cough syrup deaths, considers advice to parents (Reuters, January 24, 2023)
WHO urges action to protect children from contaminated medicines (WHO, January 24, 2023)
WHO urges action after cough syrups linked to more than 300 child deaths (The Guardian, January 24, 2023)
The inaction of Indian drug regulators on cough syrup deaths (Economic Times, January 23, 2023)
Mind your medicine (The Telegraph, January 20, 2023)
Burn after reading: FDA blasts Intas for “cascade if failure” after investigations finds heaps of shredded documents (FiercePharma, January 20, 2023)
Inconsistent drug regulation spells danger for India’s global pharma ambitions (BMJ, January 13, 2023)
Lethal Indian cough syrup strikes again (Splainer, January 13, 2023)
How did 70 Gambian and 19 Uzbek children die? (Herald Goa, January 13, 2023)
Cough syrup linked to 20 kids’s deaths was circulating for months (Bloomberg, January 12, 2023)
Behind the Indian cough syrup that killed many in the Gambia and Uzbekistan (Frontline-Hindu, January 12, 2023)
WHO issues new warning on Indian cough syrup after 18 more child deaths (Washington Post, January 12, 2022)
India’s lax oversight of pharmaceutical manufacturing imperils health around the world (STATNews, January 9, 2023)
From Whistleblower, Dinesh Thakur’s long road to reforming India’s pharmaceutical industry (ET Prime, January 9, 2023)
A scandal rocks India’s pharmaceutical industry (The Economist, January 5, 2023)
The Truth about Drug Regulation in India (The India Forum, January 5, 2023)
Jailed for doing bad business: Why GOI should reconsider provisions of Jan Vishwas Bill that decriminalizes criminals (Economic Times, January 5, 2023)
Cough syrup deaths will still not wake Indian authorities (Times of India, January 2, 2023)
Cough syrup deaths: India must focus on systemic gaps over pharma reputation (The Quint, December 31, 2022)
Cough syrup deaths: India’s drug regulator must stop treating public health crises as public relations problems (Indian Express, December 30, 2022)
Uzbekistan kids deaths bought ‘Bad Name to India’- Firm’s membership suspended (News18.com, December 30, 2022)
Indian pharma under scrutiny again after 18 Uzbek child deaths (Aljazeera, December 29, 2022)
Killer Syrup 2.0: Uzbekistan reports cough syrup deaths after Gambia (NDTV, December 29, 2022)
After Gambia, deaths of 18 children in Uzbekistan linked to India-made cough syrup (Mojo Story, December 29, 2022)
Bitter medicine for pharma regulation (Business Standard, December 28, 2022)
Uzbekistan says 18 children died due to cough syrup made by Indian firm Marion Biotech (Scroll.in, December 28, 2022)
Another Gambia type situation? Did 18 children did after consuming cough syrup made in India? (Firstpost, December 22, 2022)
10 unmissable books of 2022 on business, economics and finance (The Mint, December 28, 2022)
Only if the truth could come in a pill (Financial Express, December 18, 2022)
Delay in quality tests: Why Keralites consuming substandard medicine (Manorama Online, December 15, 2022)
Why India needs a national law to recall drugs (Mint Lounge, December 15, 2022)
“The Truth Pill”: A lonely man’s fight agains poorly regulated Indian pharmaceutical industry (Scroll.in, December 10, 2022)
Book Review: The Truth Pill (India Today, December 9, 2022)
Clearing the mess in India’s Drug Regulatory System (All Things Policy, December 9, 2022)
Remedies for a broken system: Drug Regulation in India (Artha Global, December 6, 2022)
3 years on, no chargesheet in case of 12 kids’ death in J&K (The Tribune, November 27, 2022)
82 kids had acute kidney injury, 70 died : Gambia (The Tribune, November 26, 2022)
Book Review: The Truth Pill – The Myth of Drug Regulation in India (Hindu Business Line, November 25, 2022)
Most countries wont forgive deaths of children (Rediff.com, November 22, 2022)
‘A very worrying scenario’: Internal documents on India’s Covid-19 vaccine raise troubling questions about approval process (STATNews, November 15, 2022)
‘Unimaginable Shame’: Narayana Murthy on Deaths due to Indian cough syrup (NDTV, November 15, 2022)
Viatris insider trader scheme busted (Yahoo Finance, November 15, 2022)
Know your author-Prashant Reddy (YouTube, November 12, 2022)
Review: The Truth Pill: The myth of drug regulation in India (Hindustan Times, November 12, 2022)
Mumbai’s JJ Hospital to The Gambia: 36 years apart but familiar story of deadly toxic drugs (Scroll.in, November 11, 2022)
A Truth Pill in a Bottle of Lies (Moneylife, November 11, 2022)
Know your author-Simon and Schuster (YouTube, November 11, 2022)
Toxic cough syrup and poor quality control (ABC Australia, November 5, 2022)
Indian drugs are a global lifeline. For 70 children, they were deadly (NY Times, November 3, 2022)
Banten Paracetamol Syrup producer uses chemical 100x safe limit (Jakarta Globe, November 1, 2022)
New drugs bill is wolf in sheep’s clothing (The Probe India, October 31, 2022)
Cough medicine deaths highlight India’s problem with substandard medicine (Healthpolicy Watch, October 31, 2022)
After Gambian tragedy, Indonesia bans cough syrups (SciDev, October 28, 2022)
India’s massive pharma industry hounded by scandals (DW, October 26, 2022)
How safe are drugs we take, with Dinesh Thakur (Indian Express, October 30, 2022)
Cough Syrup deaths: Why is India’s drug regulator going after Dinesh Thakur and Prashant Reddy T (Newslaundry.com, October 26, 2022)
Cough Syrup deaths: If media doesn’t hold the government accountable, who will? (Newslaundry.com, October 27,2022)
Duo behind a 6 year long crusade to uncover loopholes in India’s medicine manufacturing (The Better India, October 26, 2022)
Tharoor Line: Indian drug firms need a heavy dose of quality check (Manorama Online, October 28, 2022)
Indian site for Jubilant Generics lands Form 483 with with QC issues (EndPoint News, October 26, 2022)
US FDA issues import alert on Glenmark Pharma’s Baddi plant (Moneycontrol.com, October 26, 2022)
What do we know about contaminated cough syrup linked to child deaths (TRT World, October 24, 2022)
Gambia cough syrup deaths – adulterated medicines in India (The Lamppost, October 24, 2022)
33 years after deaths at JJ hospital due to adulterated glycerine, no lessons learnt (Times o India, October 24, 2022)
Dinesh S Thakur and Prashant Reddy T’s book “The Truth Pill’ : Exposing underbelly of pharma business (The Tribune, October 24, 2022)
Unregulated, out of control: Drug Manufacturing in India (Deccan Herald, October 24, 2022)
Quá khứ tai tiếng của thuốc Ấn Độ: Từng có loại siro khác liên quan hàng loạt ca tử vong (Vietnam,net, October 23, 2022)
India’s pharma sector has much to answer (Hindustan Times, October 23, 2022)
In de ‘apotheek van de wereld” is de control gebrekkig (NRC, October 23, 2022)
Guest in the newsroom (Lallantop, October 22, 2022)
CDSCO sends notice in the case of Gambian deaths related to cough syrup (Newslaundry.com, October 22, 2022)
Here is what we know about the cough syrup scandal (NY Times, October 22, 2022)
Serial offender Lupin lands 17-observation write up at an Indian biotech plant (Fierce Pharma, October 21, 2022)
US FDA issues Form 483 with 17 observations to Luipin’s biotech facility in Pune (CNBC TV18, October 21, 2022)
Gambia children death case: What ails India’s drug regulatory system (BQPrime, October 19, 2022)
Can we trust India’s drug regulator? Dinesh Thakur & Prashant Reddy weigh in (Forbes India, October 20, 2022)
Cough syrup deaths expose a lax drug regulation in India (The Lancet, October 22, 2022)
CDSCO warns of legal action against Thakur & Reddy for failing to withdraw statements tarnishing CDSCO’s image (Pharmabiz, October 19, 2022)
Launch of The Truth Pill (YouTube, October 15. 2022)
The role of the regulator is to protect the public, not pharma companies (Article-14, October 19, 2022)
Indian activists ask drug regulator to accept responsibility for Gambia child deaths (The Standard, October 18, 2022)
Contaminated cough syrup from India linked to 70 child deaths. Its happened before (NPR, October 18, 2022)
What ails our drug regulatory system (BQ Prime, October 18, 2022)
Jailed in Punjab, acquitted in Bengal – How judiciary handled drug law violations (The Print, October 18, 2022)
PM Modi’s advice to prescribe Generic drugs could be dangerous because they are substandard (The Wire, October 18, 2022)
Suit threat against activist, lawyer for questioning CDSCO’s role in Gambia deaths (The Telegraph, October 18, 2022)
India must act on drug adulteration-lives around the world are at stake (The Guardian, October 17, 2022)
India bashing WHO on cough syrup fiasco is old tale of pot calling the kettle black (News18, October 17, 2022)
When Byculla was Gambia (Hindustan Times, October 17, 2022)
Cough syrup deaths: Why drugs made in India are sparking safety concerns (October 17, 2022)
Feeding cough syrup seems like Russian Roulette (The Print, October 16, 2022)
Contaminated cough syrup linked to 66 child deaths in Gambia (Chemistry World, October 14, 2022)
Deaths in Gambia must push us to fix drug regulation (The Mint, October 13, 2022)
Of drug quality, Gambia and India: an interview with the authors of The Truth Pill (The Hindu, October 13, 2022)
Answered: Six questions about cough syrup deaths linked to Haryana firm (The Mint, October 13, 2022)
Cough Syrup scandal: How did it end up in the Gambia (BBC, October 12, 2022)
India halts cough syrup production at factory after Gambia deaths (Al Jazeera, October 12, 2022)
Maiden Pharma: Why should your license not be suspended/cancelled? asks CDSCO show cause notice (SouthFirst.com, October 11, 2022)
Interview with Razia Iqbal on BBC Newshour about deaths of children in the Gambia (BBC, October 12, 2022, timestamp: 45 min)
Maiden Pharma skipped key testing in cough syrup: Notice (Hindustan Times, October 12, 2022)
India owes Africa a moral duty to ensure only high quality drugs are exported (Times of India, October 9, 2022)
Gambia Deaths: Pharma company issued show cause notice by Haryana authorities (Hindustan Times, October 9, 2022)
Who is responsible for the deaths of 66 children in the Gambia (The Wire, October 11, 2022)
Haryana Govt halts Maiden Pharma’s production & issues show cause notice: Bad Medicine (CNBC TV18, October 12, 2022)
Gambia Cough Syrup Deaths: Are India-made drugs safe? Author of Truth Pill speaks (Moneycontrol.com. October 12, 2022)
Action against Haryana Pharma company: Dangerous cough syrup being sold in India? (NDTV, October 12, 2022)
Maiden Pharma: Why should your license not be suspended/cancelled? asks CDSCO (Southfirst.com. October 11, 2022)
Multiple violations found during inspections at Sonepat drug firm (The Tribune, October 9, 2022)
Podcast: Gambia cough syrup deaths- How safe are India made drugs (The Quint, October 11, 2022)
‘Truth Pill’: This book examines how some Indian drugs get away without meeting quality standards (Scroll.in, October 11, 2022)
Strengthen Drug Regulatory Framework (Hindustan Times, October 11, 2022)
Poisonous Prescriptions: The dark side of Indian pharma comes out with Africa’s cough syrup deaths (The Economic Times, October 11, 2022)
Cough Syrup row: “Habitual Offender” firm cleared to export drugs (Indiatoday.in, October 8, 2022)
India’s pharma industry’s problems need to be fixed, now (Moneycontrol.com, October 8, 2022)
India needs a national drug recall law without further delay (Economic Times, October 8, 2022)
The rise and rise of antibiotic use in India (Vice.com, October 7, 2022)
Spurious Syrup: All five accused on bail, cops yet to file challan (Tribune India, October 7, 2022)
“Killer” cough syrup: Deadly lapses in Drug Laws: Left Right & Center (NDTV, October 6, 2022)
Book highlights burning drug regulation issues in India (The Week, October 6, 2022)
Bad Medicine: Shereen Bhan in conversation with Dinesh Thakur and Prashant Reddy (CNBC TV 18, October 6, 2022)
Four states in India find NSQ drugs made by Maiden Pharma (NDTV India, October 7, 2022)
When cough syrup kills: How safe are India’s drugs (Mojo Story, October 7, 2022)
Cough syrup deaths in the Gambia linked to an Indian manufacturer (The World, October 6, 2022)
A missed opportunity: New Drugs Bill is old medicine in new bottle (Deccan Herald, September 29,2022)
Doctor-Pharma nexus Part II: W`hat drives drug prescription in India (Moneycontrol.com,. September 23, 2022)
Some cures, some lingering ailments (Financial Express, September 8, 2022)
A missed opportunity to put drug regulations in place (The Leaflet, September 2, 2022)
How deep runs the rot in the pharma sector? (Biospectrum India, 30 July 2022)
India must regulate its Drug Regulatory Body first (News18.com, June 27, 2022)
Kickback charges return to haunt India’s drug regulator (Moneycontrol, June 24, 2022)
Indian Council of Medical Research public database not “permanent” (The Telegraph, June 19, 2022)
Bad Medicine: Fake history, post-colonial complicity: Ayurveda in the time of Covid (The Wire, Sept 16, 2021)
Trial and Error (Tatsat Chronicle, June 16, 2021)
Indemnity to Covid-19 vaccine makers: A double-edged sword (Informist, July 5, 2021)
Why wont pharmacies fill prescriptions with authorized generic drugs (People’s pharmacy, May 31, 2021)
Getting clinical practice guidelines right is critical for India to control the pandemic (Scroll.in, May 30, 2021)
Is the pandemic the wake up call we need on the drug regulatory process (The India Forum, May 21, 2021)
Judge OKs classes in case accusing Ranbaxy of delaying drugs (Reuters, May 17, 2021)
Fighting fakes in Pharma: The problem isnt new (Financial Times, May 14, 2021)
India is suffering immensely under the weight of Covid. Now its failures are threatening much of the world (STATNews, May 5, 2021)
India, Brazil and human cost of sidelining Science (Nature, May 04, 2021)
“There are so many hurdles” Indian scientists plead with government to unlock Covid-19 data (Science, May 04, 2021)
Is Russia’s Covid-19 vaccine safe? Brazil’s veto of Sputnik V sparks lawsuit threat and confusion (Science Magazine, April 30, 2021)
Why is India having a Covid-19 surge? (BMJ, April 30, 2021)
Will India’s devastating Covid-19 surge provide data that clear up its death ‘paradox’? (Science Magazine, April 30, 2021)
90 suffer Remdesivir side effects:Brand Suspended (Mumbai Mirror, April 30, 2021)
Covid crisis boosts India’s trade in fake medicines (Financial Times, April 27, 2021)
DCGI approves Virafin for Moderate COVID. Where’s the evidence it works? (The Wire, April 24, 2021)
Episode 170: Katherine Eban – Bottle of Lies (Low Carb MD Podcast, April 12, 2021)
India shouldn’t insist on “bridging trials” in the middle of the pandemic (STATNews, April 7, 2021)
Pfizer’s newest vaccine plant has persistent mold issues, history of recalls (KHN News, March 11, 2021)
Insider alleges Eli Lilly blocked her efforts to sound alarm about US drug factory (Yahoo News, March 11, 2021)
What’s in that prescription medicine bottle (No Patient Left Behind, March 1, 2021)
Doctors question Health Minister’s ethics for being at Ramdev’s event (The Telegraph, February 21, 2021)
Portions of report on CDSCO’s drug approval process missing: HC pulls up the DCGI (Outlook, February 18, 2021)
Delhi HC pulls up DCGI, expresses shock on missing report (Indian Express, February 18, 2021)
Row over Zydus vaccine trials as Noida seals illegal lab (Times of India, February 18, 2021)
5 of a private lab in Noida detained for “unauthorized” Covid19 vaccine (Hindustan Times, February 18, 2021)
Controversy swirls around India’s homegrown Covid vaccine (Bloomberg, February 2, 2021)
How ICMR and Others spun Covaxin’s Phase 1 Trial results out of context (The Wire, January 24, 2021)
What India can learn from Covid-19 to build a healthier nation (Forbes, January 17, 2021)
Vaccines are safe but we dont know how effective they are as we dont have data, says virologist Shahid Jameel (Times of India, January 17, 2021)
ISRC Symposium on India’s vaccine policy (January 17, 2021)
Dont want to be guniea pigs: Most govt hospital workers in Delhi refuse to take Covid-19 vaccine (National Herald, January 17, 2021)
India launches vaccine drive as scepticism mounts (Financial Times, January 16, 2021)
India kicks off a massive Covid-19 vaccination drive (NPR, January 16, 2021)
Here’s why I will not take the Covid-19 vaccine: JNU Professor Vikas Bajpai (Outlook Magazine, January 16, 2021)
Why is India buying an untested vaccine when a cheaper option with better safety data is available (Scroll.in, January 15, 2021)
Doctors call for investigation into allegations of ethical abuse in Covid-19 vaccine trial (BMJ, January 14, 2021)
With Covid-19 approvals, ‘vaccine nationalism’ is a worrisome trend (STATNews, January 14, 2021)
India prepares for massive vaccine drive, but some fear it is moving too quickly (NPR, January 13, 2021)
India’s Covid-19 vaccine trial participants claim they were misled (Indiaspend.com, January 11, 2021)
How India’s regulatory pitfalls helped Covidshield and Covaxin gain rapid approval (The Print, January 8, 2021)
Criticism mounts over India’s abrupt approval of COVAXIN (Reuters, January 6, 2021)
Minutes show how panel changed its mind on Covaxin (Indian Express, January 6. 2021)
How expert panel gave nod to to Bharat Biotech’s Covaxin: What minutes of meetings reveal (News18.com, January 6, 2021)
Activists question panel’s change in stance on Covaxin in four days (Times of India, January 6, 2021)
Coronavirus: Bharat Biotech vaccine approved in clinical trial mode (Scroll.in, January 6, 2021)
Covid-19: In a rush to declare ‘Atmanirbhar vaccine” is India playing with fire? (Scroll.in, January 6, 2020)
Sudden change of mind due to government pressure? Minutes show expert panel’s Covaxin somersault (The New Indian Express, January 6, 2021)
India’s vaccine nationalism is a global risk (Washington Post, January 6, 2021)
Wont take Covaxin until efficacy data is made public:Gagandeep Kang (The Wire, January 6, 2021)
India’s Covid19 vaccine: Nationalism, Symbolism and Realism (ORF Online, January 6, 2021)
DCGI’s Covaxin approval is a political jumla. It reinforces the idea of Atmanirbhar Bharat (The Print, January 6, 2021)
Covaxin:What was the rush to approve India’s homegrown vaccine? (BBC, January 6, 2021)
Vaccination against Foot & Mouth disease: Punjab halts drive as Hyderabad firm’s fails vaccine quality test (Indian Express, January 6, 2021)
Scientists criticize “rushed” approval of Indian Covid-19 vaccine without efficacy data (Science, January 6, 2021)
Experts voice concerns on India’s Covid-19 vaccine approval process (Bloomberg Quint, January 4, 2021)
Book Review: Bottle of Lies ( December 16, 2020)
Covid-19 patients are being treated with drugs such as Itolizumab even though there is insufficient evidence on their efficacy against the disease (Frontline Hindu, December 20, 2020)
How will Moderna meet the demand for its Covid-19 vaccine (NPR, December 18, 2020)
India’s drug regulator has failed the pandemic stress test (STATNews.com. December 11, 2020)
Serum Institute fracas exposes loose ends of India’s Clinical Trial machinery (The Wire, December 10, 2020)
SII seeks emergency nod but adverse events raise critical questions (The Quint, December 9, 2020)
Who will be policing the quality of the Covid-19 vaccine (The Mint, November 24, 2020)
Drugs & Cosmetics Act 1940: Recommendations for a revamp (Express India, November 20, 2020)
Covid-19: Government’s tacit approval of traditional medicine treatments alarm Indian doctors (BMJ, November 15, 2020)
Scientists criticize use of unproven Covid drugs in India (Nature, November 9, 2020)
‘Bottle of Lies’ author Katherine Eban on investigating big Pharma (ICJ, October 5, 2020)
No incentive for quality in generic drugs world (Forbes India, October 5, 2020)
How Covid numbers were hushed up (The Telegraph, September 20, 2020)
4 years on, promised mandatory pharma ethics code is elusive (Times of India, August 24, 2020)
Pharma industry: Testing times (Legal India, August 22, 2020)
Hundreds of clinical trials underway in India, many lack vigor, expert say(Indiaspend.com, August 20, 2020)
Make Covid drug trials transparent, fix regulation to make more regulation, trial data public(Financial Express, August 12, 2020)
Another cough syrup from the same Himachal Pradesh Firm, same expiry lands kid in ICU(Indian Express, August 12, 2020)
Trump orders to buy American medicines only and impact on Indian pharma industry (Fox Exclusive, August 10, 2020)
Seizing on India’s lax standards for Covid-19 drugs, critics push for an overhaul on transparency (STATNews, August 10, 2020)
Trump order boosts US drug industry, no hit on India exports in the short term: Experts(Indian Express, August 10, 2020)
DCGI asks drug controllers to prevent sale, distribution of DEG contaminated cough syrup, Cofset(Indian Express, August 7, 2020)
Health Minister petitioned: Medical professionals seek transparency in pharma regulations(Indian Express, August 7, 2020)
Government notifies over 450 Fixed Dose Combinations as Rational (Economic Times, August 7, 2020)
Fact checking during a pandemic: A response to the Telegraph and Biocon(Newslaundry.com, August 6, 2020)
India’s yogi tycoon angers critics with coronavirus “cure” kit(Financial Times, August 5, 2020)
Itolizumab for Covid-19: Who benefits when the drug regulator is opaque?(The Wire, July 31. 2020)
Cloud on Itolizumab after CDSCO approval(The Telegraph, July 27, 2020)
An opaque model for drug approval in India(The Telegraph, July 27, 2020)
Biocon to give more data on Itolizumab to Covid task force after its rejection for treatment (The Print, July 27, 2020)
The scandal of our drug supply (NYBooks Review, July 23, 2020)
Pharmacy Podcast(July 23, 2020)
Hurried nod for Covid-19 drugs: Indian drug regulation authorities under scanner(The New Indian Express, July 20, 2020)
Glenmark’s Favipiravir under government scanner for false claims, cost; DCGI seeks clarification (The Print, July 19 2020)
COVID-19 Ayurveda medicine trials opposed(The Hindu, July 18, 2020)
Did Coronil violate clinical trial norms? Doctors, experts seek MCI intervention(The New Indian Express, July 15, 2020)
Clinical Trials “wanting” for Itolizumab and Tocilizumab (The Hindu Business Line, July 15, 2020)
India’s Ayush industry needs an entirely new regulatory model(The Mint, July 9, 2020)
Unsustainable low prices causing Generic Drug market failure leading to supply chain disruptions and shortages (Forbes, July 6, 2020)
Life saving Covid drug in short supply, prices shoot up(Indiaspend.com, July 6, 2020)
Clinical Trial Database hole (The Telegraph, July 3, 2020)
How Patanjali’s magic didnt work on Covid (The Mint, June 30, 2020)
Secrets & Lies: Fake data and lack of transparency plague global manufacturing(CBC, June 26, 2020)
Ramdev’s Ayurvedic medicine for Covid-19 has kicked up quite a storm (qz.com, June 25, 2020)
The many questions about Favipiravir (The Hindu, June 25, 2020)
State must stop putting our lives in danger with poor quality medicines(The Standard, June 19, 2020)
A dose of reality about generic drugs(TedMed, June 17, 2020)
Five key takeaways from the Senate hearing on FDA oversight of foreign manufacturing(Lexology, June 4, 2020)
Reliance on foreign drug makers wont wane with virus, says FDA (Bloomberg Law, June 2, 2020)
A report on drug regulator CDSCO’s “irregular” approvals has gone “missing”(The Wire, June 3, 2020)
CDSCO faces CIC ire over “misplaced” 2013 report on “irregular” approval of drugs (Indian Express, June 2, 2020)
Missing files at DCGI: CIC seeks action, digitization of records(Economic Times, May 30, 2020)
Pharma sector’s survival factor (Corporate Citizen India, May 30, 2020)
How the Generic drugs we take may not be what they seem (Carnegie Foundation, May 28, 2020)
Bound by Science, bent by Politics: Inside the FDA’s reversals and walkbacks as it grapples with the Coronavirus pandemic (CNN, May 22, 2020)
Safeguarding & Streamlining Pharma Supply Chain: Time for mandating certified drugs (Forbes, May 7, 2020)
Drug Dependence: Covid-19 weakens already fragile US drug supply (Investigate TV, May 6, 2020)
Trump’s Virus drug costs millions, even as the mania wanes (Bloomberg, May 5, 2020)
Book Review: ‘Bottle of Lies’ exposes the dark underbelly of Indian pharma (Moneycontrol.com, May 4, 2020)
The world needs to change how it trades drugs (Foreignpolicy, April 21, 2020)
Who’s afraid of the WHO? (IndianExpress, April 16, 2020)
Spikes in demand from coronavirus patients are creating shortage for asthma drugs and sedatives for ventilator patients(Washington Post, April 13, 2020)
Next potential shortage: Drugs needed to run ventilators (Associated Press, April 10, 2020)
Coronavirus fuels a surge in fake medicines (BBC, April 10, 2020)
Troubled overseas drugmakers get a free pass in coronavirus crisis (Bloomberg, April 9, 2020)
US is suddenly OK with Indian Chloroquine maker it banned for multiple violations (Huffington Post, April 8, 2020)
Pressed by Trump, US pushed unproven coronavirus treatment guidance (Reuters, April 4, 2020)
Which public authority should be in charge of India’s policy on diagnostic kits for COVID-19?(Scroll.in, April 3, 2020)
‘Bottle of Lies’ wins the Overseas Press Club of America award for non-fiction book, April 2, 2020
Death of Assam doctor raises questions about malaria drug recommended for COVID-19 treatment (Scroll.in, April 2, 2020)
FDA authorizes widespread use of unproven drugs to treat coronavirus, saying possible benefit outweighs risk (Washington Post, March 30, 2020)
Covid-19 and drug quality uncertainity: What to do about it(AEI, March 30, 2020)
India risks Covid-19 testing chaos as ICMR keeps cards close to its chest(The Ken, March 30, 2020)
Assam doctor who took anti-malaria drug amin Covid-10 outbreak dies(Hindustan Times, March 30, 2020)
The latest on Hydroxycholoroquine for Covid-19(People’s pharmacy, March 30, 2020)
The COVID-19 pandemic increases the chance that your other medicines wont work (Medium, March 29, 2020)
Virus likely curtailed China drug output, raising shortage fears(Bloomberg, March 25, 2020)
FDA lifts import curbs on maker of unproven CoVid-19 drug in India(Bloomberg, March 23,2020)
How Coronavirus is affecting US Pharmaceutical Supply (NPR, March 12, 2020)
Why lethal cough syrup slipped past the law (Indian Express, March 13, 2020)
Behind killer cough syrup Coldbest: Glaring gaps in regulation in its manufacture(Indian Express, March 12, 2020)
FDA halts overseas inspections of drugs and devices, citing Coronavirus(NYTimes, March 10, 2020)
Shaken by Corona virus crisis, India looks to become bulk drugs major to cut China imports (The Print, March 2, 2020)
How syrup to cure cold, fever proved fatal for kids (The Tribune, February 29, 2020)
Meghalaya: At least 250 bottles of cough syrup with poisonous compound seized(The North East Today, February 29, 2020)
State lethargy amidst cough syrup poisoning (The Hindu, February 29, 2020)
Newslaundry interview of Bottle of Lies (Newslaundry, February 29, 2020)
Lallantop interview of Bottle of Lies (Lallantop, February 28, 2020)
Anti-TB drug Delamanid drying out, Center yet to receive new stocks from Japan (Hindu Business Line, February 28, 2020)
India among top supplier of Pharma drugs used in trafficking: UN Report(Hindu Business Line,. February 27, 2020)
Killer medicine(Indian Express, February 27, 2020)
Cough Syrup had nothing to do with children deaths: Digital Vision owner (Economic Times, February 26, 2020)
Himachal government to file FIR against cough syrup makers ‘responsible’ for 10 infant deaths (The Print, February 26, 2020)
Under scanner for 11 deaths, 3400 bottles of cough syrup sold (Indian Express, February 26, 2020)
Deaths in Jammu due to cough syrup: A grim reminder of drug regulation laxity (Moneycontrol.com, February 22, 2020)
“Killer cough syrup” maker failed quality tests several times(Times of India, February 22, 2020)
Cough syrup Coldbest-PC recalled, production halted after 9 deaths in Jammu(Indian Express, February 20, 2020)
India lists 38 drug materials for which it wants to end dependence on China (The Print, February 19, 2020)
Sun Pharma, others on regulator’s radar as drugs flunk quality tests(The Mint, February 19, 2020)
Several drugs at Jan Aushadhi Kendras recalled over quality tests(Deccan Herald, February 14, 2020)
From March 2021, pharma firms marketing drugs will be held responsible for quality (Hindu Business Line, February 14, 2020)
Drug marketers to be held responsible for quality(Economic Times, February 14, 2020)
Why people should know what’s in their medicines(European Pharmaceutical Manufacturer, February 14, 2020)
Indian Generic Drug makers may face supply shortages from China if Coronavirus drags on (US News and World Report, February 13, 2020)
Medical Device Norms (The Telegraph, February 12, 2020)
We still dont know who makes this drug (Healthaffirsblog.com, February 8, 2020)
Book review: Bottle of Lies (Hindustan Times, February 7, 2020)
NL Interview: Katherine Eban on Pharma’s corrupt practices (Newslaundry, February 5, 2020)
Generic Drugs: Eban’s book exposes the rot in the system (Bloomberg Quint, February 3, 2020)
Our pharma regulator must wake up (The Hindu Business Line, January 30, 2020)
OAI classifications for Drug, Device Facilities decline sharply over the last five years (RAPS, January 20, 2020)
What Ranbaxy and Indian pharma dont want you to know: Katherine Eban(Indian Express, January 26, 2020)
FDA keeps brand name drugs on fast path to market – despite manufacturing concerns(KHN News, January 23, 2020)
DMF Submissions in 2019: India maintains bulk drug supremacy in the US (Pharmacompass, January 23, 2020)
Pain for big Indian pharma companies continues, warns CRISL as FDA woes remain unresolved (Economic Times, January 21, 2020)
US pharma companies get more FDA warnings than Indian firms (Times of India, January 20, 2020)
Indian pharma fraud & beyond (Economic & Political Weekly, 18 January, 2020)
Operation Kota: Milk for babies used to make tea, docs absent, infants exposed to rodents (India Today, January 18, 2020)
It has been a defining decade for clinical trials (Hindu Business line, January 18, 2020)
Drug regulator flags 47 medicines for failing quality tests(Indian Express, January 17, 2020)
Time the pharma sector was refurbished (The Tribune, January 17, 2020)
Generic Fail: Lack of oversight in Generic Drug Manufacturing (Fututetech podcast, January 15, 2020)
Center mulling action to counter US jounalists’s allegations against Indian pharma (The Wire, January 15, 2020)
49 medicine samples fail regulator’s quality tests (The Mint, January 15, 2020)
California government proposes that the state manufacture its own generic drugs (Pharmacytimes, January 13, 2020)
Talking of whistleblowing in the age of fraud and much more (The Tribune, January 12, 2020)
California lab finds new clues in popular heartburn drug’s possible cancer link(CBS News, January 10, 2020)
Modi government plans action against US writer who said Indian drugs are “flea-market quality” (The Print, January 10, 2020)
Why India depends heavily on China for raw materials? (HealthAnalyticsAsia, January 3, 2020)
A tribute to the whistleblower, risking job and even life (The Tribune, January 5, 2020)
Ranitidine impurity scare: Many doctors say they still have faith in the age-old drug(Moneycontrol.com, January 4, 2020)
Carcinogen in Heartburn drug may build in storage, lab finds (Bloomberg, January 3, 2020)
In HP, health department made illogical purchase of drugs, machinery: CAG (Economic Times, January 3, 2020)
Bottle of Lies proves a bitter medicine for the DCGI (Hindu Business Line, January 3, 2020)
Drugs for TB, Hypertension and Antacids amongst those failing quality tests(The Mint, December 24, 2019)
TB antibiotic, acid reflux drug among 37 batches flagged for failing quality tests(Indian Express, December 24, 2019)
New CDSCO disclosure reveals quality of medicines sold in India (The Wire, December 22, 2019)
How the future of Fortis Healthcare rests on the outcome of high stakes battle(Economic Times, December 22, 2019)
Why your generic drugs may not be safe and the FDA may be too lax (UConn Today, December 18, 2019)
How do you stop taking recalled mediation?(Bloomberg, December 15, 2019)
LA Times Opinion: Why you should worry about drug companies’ reliance on Chinese ingredients(LA Times, December 11, 2019)
Why your generic drugs may not be safe and the FDA may be too lax (Philadelphia Inquirer, Dec 11, 2019)
Can Generics fill existing quality gaps(ET Healthworld, December 11, 2019)
Drug plant inspections ebbed as tainted drugs flowed into the US(Bloomberg, December 10, 2019)
Generic drugs revisited(Mumbai Mirror, December 10, 2019)
FDA embraces generic drugs from India despite quality problems (People’s pharmacy, Decembe 6, 2019)
Pharma’ s take on Pelosi’s drug pricing bill: Fair warning or fearmongering? (KHN News, December 6, 2019)
Chennai: Most spurious medicine samples seized in the state(ET Health, December 5, 2019)
Grand Tamasha Podcast: Katherine Eban on Generic Drugs (December 4, 2019)
Indian drug makers arent losing sleep despite getting a record 23 warning letters from the US FDA (theprint.in, December 3, 2019)
Will Aurobindo pharma be able to find a cure for its US FDA woes? (Bloomberg Quint, November 27, 2019)
CDSCO flags drugs made by 3 PSUs for failing quality tests(Indian Express, November 26, 2019)
Betnovate, Panderm samples fail quality tests; makers say products counterfeits (Indian Express, November 25, 2019)
In the absence of a comprehensive law, how employee whistleblowers fare (Economic Times, November 24, 2019)
India’s dependence on Chinese API reaches max over the last three years (Hindu Business Line, November 22, 2019)
Torrent pharma warned by US again, this time for using bacteria-contaminated water system (theprint.in, November 21, 2019)
How the Supreme Court’s iron hand will affect Fortis-IHH deal (The Hindu BusinessLine, November 20, 2019)
#Implantfiles: On blacklist in the US, in India they are in grey zone (Indian Express, November 18, 2019)
13 drugs manufactured in Himachal Pradesh fail quality tests (Hindustan Times, November 14, 2019)
Are Good Manufacturing Practices no longer enough (Pharmaceutical Online, October 28, 2019)
Mylan plant knocked for sloppy manufacturing controls in gained Valsartan fiasco (FiercePharma, November 13, 2019)
10 years on, Government’s 6 Cr Vaccine Complex fails to take off (Moneycontrol.com, November 13, 2019)
Few inspectors, no records, poor communications mar India’s drug regulation (Healthcheck.in, November 12, 2019)
What has Zantac recall cost drugmakers? (FiercePharma, November 11, 2019)
New policy likely to resolve drug name anomaly (Economic Times, November 8, 2019)
Why India’s Health sector needs more data transparency (Health Analytics Asia, November 8, 2019)
Come 2023, generic companies will be able to manufacture anti-TB drug (Hindu Business Line, November 7, 2019)
Why India needs a separate regulation for devices (Moneycontrol.com, November 7, 2019)
Indian drug makes continue to be in trouble with new FDA warning letters (The Mint, November 6, 2019)
FDA keeps brand name drugs on faster path to market – despite manufacturing concerns (The Daily Beast, November 4, 2019)
The pill economy of India’s online medicos (The Mint, November 4, 2019)
India must close the tortuous discussions on medical device regulations (Moneycontrol,com, November 4, 2019)
In generic drug plants in India and China, data falsification is still a problem (STATNews, October 29, 2019)
Katherine Eban on Bottle of Lies at the Texas Book Festival (CSPAN, October 26, 2019)
Medical devices are not drugs (October 25, 2019)
Documents potentially misleading in Aurobindo pharma’ s Unit-VII: US FDA (Economic Times, October 11, 2019)
Ranbaxy and a culture of Jugaad:What bought a leading company down(Outlook India, October 10,2019)
Conduct post-market surveillance on abdominal painkiller: CDSCO to States (Indian Express, October 8, 2019)
India’s oldest drug maker cannot help Modi government revive penicillin production (The Print, October 6, 2019)
New guidelines being planned for recall of medicines (Indian Express, October 6, 2019)
USFDA red flags Lupin for significant violations at MP unit (October 4, 2019)
Generic Drugs and Global Deception (Skepdoc, October 4, 2019)
Spurious drugs flooding Indian market, consumers suffering due to data fraud (Outlook Magazine, October 4, 2019)
Why India, US havent recalled acidity drug Ranitidine, but France and Canada have (The Print, October 2, 2019)
After a scandal, a one-sided warning against generic drugs (Washington Post, September 13, 2019)
US, EU probing carcinogens detected in versions of Zantac (Bloomberg, September 13, 2019)
FDA uncovers a “cascade of failure” at IPCA Laboratories in India (Pharmacompass, September, 12, 2019)
Carcinogens have infiltrated the generic drug supply in the US (Bloomberg, September 12, 2019)
China’s grip on pharmaceutical drugs is a national security issue (Washington Post, September 11, 2019)
Harrowing portrait of generic drug industry shows us why regulators need to show up (Center for health journalism, September 10, 2019)
UP: Medicines that fail lab tests find their way to district hospital; stock sealed (Times of India, September 10, 2019)
Whistleblower Vs Ranbaxy saga asks difficult questions (Deccan Herald, September 8, 2019)
Why the Indian pharma industry needs to act now to win back the trust it lost (The Wire, September 8, 2019)
Levothyroxine Formulations: Clinical and phrmacological implications of generic substitution (Springer, September 7, 2019)
How moves toward Universal Health Coverage could encourage poor quality drugs (BMJ, September 4, 2019)
Water leaks fixed with zip-ties indicative of Dr. Reddy’s sterile plant failings (Fiercepharma, September 3, 2019)
FDA analysis of top cGMP inspection citations in FY 2018 (Pharmaceutical Online, September 3, 2019)
Generic Drugs & Global Deception (sciencebasedmedicine.org, September 3, 2019)
The CDSCO is blowing in the wind (Indian Express, August 28, 2019)
China’s new drug law may open door for Indian generics (Financial Express, August 27, 2019)
The dangerous cocktail of substandard drugs and substandard drugs in India (Moneycontrol.com, August 25, 2019)
In the end, the book and the truth won out (The Week, August 24, 2019)
Capping a scandal (The Week, August 24, 2019)
Shopping abroad for cheaper medication? Here’s what you should know (Pittsburg Gazette, August 24, 2019)
Bottle of Lies: Katherine Eban shows the fraud behind India’s Generic Drug Industry (AEI, August 19, 2019)
A spring cleaning at the CDSCO (Indian Express, August 18, 2019)
US FDA warns Emcure Pharma for failing to aggressively investigate injection sterility issues (Indian Express, August 16, 2019)
BP drug complaints: Lantech Pharma gets USFDA Warning Letter (Indian Express, August 15, 2019)
Brother scientists no longer at Novartis after alleged data manipulation (CBS News, August 15, 2019)
US dependence on pharmaceutical products from China (Council on Foreign Relations, August 15, 2019)
US FDA pulls Emcure Pharma for manufacturing violations at Pune Plant (New Indian Express, August 15, 2019)
FDA cites solvent recovery firm as a player in the Valsartan mess (Fierce Pharma, August 15, 2019)
FDA tells Torrent Pharma of OAI inspection (The Pharma Letter, August 15, 2109)
The Sartan Saga: Recapping the recalls (Inpharma technologist, August 15, 2019)
To fix quality of Indian drugs, Modi govt plans to tighten storage and transportation laws (The Print, August 14, 2019)
Novartis violated FDA’s sacred principle: In God we trust, everyone else must bring data (Stat News, August 14, 2019)
The inside story of Ranbaxy’s dirty drug scandal (The Telegraph, August 14, 2019)
Eban’s expose of Indian Generics: Right diagnosis, wrong cure? (Times of India, August 13, 2019)
US Taxpayers fund antibiotics for China as Industry flails (Bloomberglaw, August 10, 2019)
CMOs and Generic Drug suppliers have the same objective, but reach their goal differently (Pharmacompass, August 9, 2019)
Heartland Institute Podcast: Corruption in the Indian Generic industry (August 8, 2019)
8 ways overseas drug manufacturers dupe the US FDA (Wired, August 7, 2019)
Indian Pharma – Reputation Gap (ET Health World, August 5, 2019)
Drug makers master rolling out their own generics to stifle competition (KHN News, August 5, 2019)
Pentagon sees security threat in China’s drug supply dominance (Bloomberg, August 5, 2019)
Foreign Generic Drugs: A matter of Life, or death (Washington Free Beacon, August 4, 2019)
“Bottle of Lies” review: Lessons from Ranbaxy (The Hindu, August 3, 2019)
Nestle violates law in India, conducts clinical trials on premature infants for baby food (National Herald, August 3, 2019)
4 major questions on HHS and FDA’s drug importation action. plan (Fiercepharma.com, August 2, 2019)
How an epic legal battle bought a secret drug database to light (Washington Post, August 2, 2019)
Compliance to determine the success of Mylan’s merger with Pfizer’s Upjohn (August 1, 2019)
Dangerous drugs, compromised regulators (The Telegraph, July 31, 2019)
The inside story of the generic drug boom (Cool Science Radio, July 26, 2019)
Ranbaxy cut corners to improve its bottom line: and it did not work (IANS, July 26, 2019)
2019 FDA Warning Letters to Biopharma companies (Biospace, July 24, 2019)
Bottle of Lies: The truth about Generic Drug Safety (RadioMD, July 2, 2019)
Effective overseas inspections are key to ensuring drug quality (The Hill, July 22, 2019)
Diagnosing the drug supply: Exposing bad practices of manufacturers in the developing world (Pharmafile, July 22, 2019)
The Indian pharma industry is in denial over drug quality charges (STATNews, July 22, 2019)
Let the patient beware Let the patient beware (American Thinker, July 21, 2019)
Delhi HD ruling clarifies requirements for export under India’s Bolar exemption (ipwatchdog.com, July 20, 2019(
How to get filthy rich in rising Asia (Mumbai Mirror, July 21, 2019)
The scary truth about generic drugs in India and China (HealthAnalyticsAsia, July 20, 2019)
Bottle of Lies: Cabinet of Neglect (Financial Express, July 20, 2019)
Katherine Eban discusses her just published book Bottle of Lies – The inside story of the Generic Drug Boom (Health Policy Podcast, July 18, 2019)
Indian pharma is not-subpar, it is ensuring the world doesnt face a healthcare crisis (The Print, July 18, 2019)
“We are in big trouble: A new book investigates the generic drug boom – alleges rampant fraud (THe Scroll, July 18, 2019)
US FDA raises doubts about Indian Pharma company’s quality control practices (The Wire, July 17, 2019)
US regulatory body accuses India’s Strides Pharma Sciences of adulteration (India Today, July 17, 2019)
Cabinet approves 330 Crore for unpaid employees of three pharma PSUs (Times of India, July 17, 2019)
An Indian drugmaker sent its record to scrapyard before the US FDA visit (STAAT, July 17, 2019)
Drugmaker shredded quality documents ahead of FDA inspection (Bloomberg, July 16, 2019)
FDA warns Strides Pharma for uncontrolled document shredding (RAPS, July 16, 2019)
Where is India’s pharma market headed? (First post.com, July 16, 2019)
The scary truth behind generic drugs in India (Hindustan TImes, July 13, 2019)
The White House’s about-face on drug rebates is loss for public-health (STAT, July 12, 2019)
US dependence on China for medicine is a major problem (The Tribune Democrat, July 12, 2019)
Trump’s losses in drug pricing battles should be a free-market wake up call for him (CNBC, July 11, 2019)
Opening Indian pharma’s bottle of lies (HealthissuesIndia.com, July 12, 2019)
Bottle of Lies Review: Pharma companies make their worst drugs for… least regulated markets, including India (Indian Express, July 11, 2019)
Pharma firms should step up regulatory compliance (The Hindu BusinessLine, July 11, 2019)
The hits keep coming: Apotex loses 31 drug approval after FDA cites plants for inadequate controls (FiercePharma, July 11, 2019)
Quality failures at a Generic Drug maker puts patients at risk (Claims Journal, July 11, 2019)
Quality failures at Generic Drug maker puts patients at risk: FDA warns (Bloomberg, July 10, 2019)
Many Indian companies putting profits over patients’ health: Katherine Eban (Economic Times, June 10, 2019)
Trump Slump: Report says FDA enforcement is way down (massdevice.com, July 3, 2019)
There is no definition of generic drugs: Ashwini Kumar Choubey (ET Healthworld, July 3, 2019)
FDA sends warning letter to Aurobindo, API Repackers (Regulatory Focus, July 3, 2019)
Trump fixates on drug prices as campaign looms (Washington Post, July 3, 2019)
India’s poorest states saw the largest declines in health sector index (Bloomberg Quint, July 3, 2019)
Bihar AES deaths: AIIMS team blames administrative failure; state apathy (Indian Express, July 3, 2019)
The Government is responsible for sky-high drug prices (Valley Patriot News, July 3, 2019)
BottleX: Exposing impurities in the Generic Drug Business (Newsweek, July 2, 2019)
FDA enforcement actions plummet under Trump (Science, July 2, 2019)
Trust issues deep as another FDA Commissioner joins the pharma industry (Quartz, July 2, 2019)
Elizabeth Warren to ex-FDA chief Gottlieb: Quit Pfizer Board (Bloomberg, July 2, 2019)
Katherine Eban on Corporate Crime in the pharmaceutical industry (Corporate Crime Reporter, July 1, 2019)
Katherine Eban on”Bottle of Lies” on KCBS Radio (June 20, 2019)
The Indian pharma industry can do better than conspiracy theories and ad-hominem attacks (ORF, June 19, 2019)
The bitter side of India’s pharma story (The Hindu, June 19, 2019)
As global markets for Gx fail, poor people pay the price (statnews.com, June 19, 2019)
India’s ailing Health Sector (The Diplomat, June 18, 2019)
Fourth carcinogen discovered in heart pills used by millions (Bloomberg, June 18, 2019)
Some low-income countries pay 20-30 times more for generic drugs (THe Pharma Letter, June 18, 2019)
WHO, Country governments must take leadership roles to ensure access to global markets for quality generic medicines (Kaiser Family Foundation, June 18, 2019)
BPPI finds 25 batches of drugs entering Jan Aushadhi to be substandard (Financial Express, June 18, 2019)
Clarify steps taken to promote Generic Medicines: Gujarat HC to MCI (DNA India, June 18, 2019)
Ranbaxy Revisited: Why we need to look back (Outsourced Pharma, June 14, 2019)
A prescription for disaster: The dangers inside the global generic drugs industry (June 14, 2019)
The Sweet Pill (Business Today, June 13, 2019)
An analysis of 2018 FDA Warning Letters citing Data Integrity (pharmaceuticalonline. com, June 13, 2019)
Overpriced and underegulated: The dark side of Generic Drugs (Adirondack Daily, June 13, 2019)
FDA hammers yet another aurobindo plant for flawed data integrity (Fierce Pharma, June 12, 2019)
Drug shortages are endangering lives and wasting NHS time (The Guardian, June 11, 2019)
Bottle of Lies: What ails India’s drug industry (Moneycontrol. com June 10, 2019)
Katherine Eban on the “Bottle of Lies” in our pill cabinets (KCBS, June 7, 2019)
CDSCO releases updated list of 2006 WHO GMO certified drug manufacturers (medicaldialogues.in, June 6, 2019)
World needs Generic Drugs but their quality must be guaranteed: Katherine Eban (Economic Times, June 8, 2019)
Generic Drug Maker Heritage Pharma admits to price fixing (HealthLeadersMedia.com, May 31, 2019)
Generic Drugs Poisonous Pill (WYNC, May 31, 2019)
Bottle of Lies: What’s behind the pharmacy to the world (Moneylife, May 31, 2019)
Generic Corruption (Business Standard, May 31, 2019)
Digging Deeper: Indian pharma tastes its own bitter medicine (MOneycontrol. com, May 30, 2019)
Are Generic Drugs Safe? (The Hill, May 30, 2019)
Public Health Activist Dinesh Thakur details dangers of generic drugs (Hill TV, May 29, 2019)
Public health activist calls for country-of-origin labels on prescription drugs (Hill TV, May 29, 2019)
Health advocate says the FDA must walk a fine line to ensure affordable drugs are safe (Hill TV, May 29, 2019)
Alert on affordable medicines (The Telegraph, May 30, 2019)
The conflict between Branded and Generic medicines in India (ET Healthworld, May 29, 2019)
Majority Report : Bottle of Lies – The inside story of the Generic Drug Boom (YouTube, May 29, 2019)
A look at generic pharma’s dark underbelly (Bloombergquint, May 28, 2019)
Editorial: The multimillion dollar cure (LA Times Editorial, May 28, 2019)
Historical trial tests whether big pharma can be held accountable for the opioid epidemic (News Channel 5 Nashville, May 28, 2019)
As generic prices decline, Indian drugmakers look to speciality and biologic products (The Pharma letter, May 27, 2019)
Why Americans are putting up with tainted drugs from foreign sources?(Newsleader, May 23, 2019)
How poor FDA oversight & fraud in generic drug industry threatens patient’s health (Democracy Now, May 20, 2019)
The man who bought Ranbaxy to its knees is pushing for “Made in India” tag on drugs sold in the US (Business Insider, May 20, 2019)
FDA defends oversight amid questions of safety of generic drugs made in India and China (USA TOday, May 17, 2019)
Pharma companies can’t sell tweaked drugs under old name (Time of India, May 17, 2019)
How some generic drugs can do more harm than good (Time, May 17, 2019)
Ralph Nader: Trump Administration importing dangerous medicines and food and keeping consumers in dark (Eurasia Review, May 17, 2019)
The Generic drugs you are taking may not be as safe or as effective as you think (NPR, May 16, 2019)
New book warns Americans against “flea-market quality” Indian generic drugs (The Print, May 16, 2019)
Heart drug suppliers for millions faulted over bugs, data (Bloomberg, May 16, 2019)
New book on quality issues in generic drugs sends FDA in damage control model (Pharmacompass, May 16, 2019)
“Bottle of Lies” Book on Generic Drugs Exposes Indian Companies (Bloomberg quint, May 15, 2019)
A frightening new book on safety of generic drugs could send India’s pharma industry into an ever deeper pit (Business Insider, May 15, 2019)
Dinesh Thakur and Erin Fox call on US Congress and FDA to hold Hearings on Generic drug safety (PREWeb, May 14, 2019)
A new book argues that generic drugs are poisoning us (NYTimes, May 13, 2019)
Bottle of Lies exposes the dark side of the generic drug boom (NPR, May 12, 2019)
Scientists upset by Ayush ministry advisory (Economic Times, May 12, 2019)
Americans need generic drugs. But can you trust them? (NY TImes, May 11, 2019)
Teva is at the center of drug fixing case outlined by states Teva is at the center of drug fixing case outlined by states Teva is at the center of drug fixing case outlined by states (Bloomberg, May 10, 2019)
Has Trump done anything to fix drug prices Has Trump done anything to fix drug prices (The Atlantic, May 10, 2019)
When to submit an ANDA Vs 505 (b)(2): FDA Explains (RAPS, May 9, 2019)
Rising concern over generic drugs (CBSN, May 10, 2019)
States allege generic drug executives deleted texts, obstructed justice in price cartel probe (Washington Post, May 10, 2019)
Questions raised over safety of generic drugs (CBS This morning, May 10, 2019)
Tainted drugs: ex-FDA inspector warns of dangers in US meds made in India, China (NBC News, May 10, 2019)
Allegations of widespread fraud raise questions about the safety of generic drugs made overseas (CBS News, May 10, 2019)
Policy support is the prescription that pharma seeks (The Hindu, May 10, 2019)
Govt offers drug firms INR 3501 Cr settlement for price cap penalties (The Mint, May 9, 2019)
Health Ministry officials attending pharma lobby summit raises eyebrows (Times of India, May 8, 2019)
Govt official participation in US health drug summit draws flak (Millennium Post, May 8, 2019)
European regulator finds cancer-causing element in diabetes medicines made in India (The Print, May 6, 2019)
Should you trust your prescription drugs (People’s Pharmacy, May 4, 2019)
India, China leading sources of counterfeit medicines: Report (The Week may 4, 2019)
THe money and politics of prescription drugs: What you need to know (Politifact, April 30, 2019)
Big win for affordable medicine (Bloomberg Quint, April 30, 2019)
No country for generic drugs (The Hindu April 29, 2019)
JnJ rejects Raj govt on presence of formaldehyde in baby shampoo (Economic TImes, April 28, 2019)
Nearly 20% of all pharma products sold in India are counterfeit, US trade body claims (The Print, April 26, 2019)
DRL recalls anto-seizure drug from the US (Indian Express, April 26, 2019)
US FDA finds quality, data issues at Dadra plant of Sun Pharma (Indian Express, April 25 2019)
Generic drugs can come with risks (NBC News, April 24, 2019)
The unseen crisis of drug shortages (Bloomberg, April 24, 2019)
India may be the “global pharmacy”, but Indians have poor access to drugs (The Telegraph, April 24, 2019)
Modi government writes to JnJ for details of surgical pelvic mesh after US ban (THe Print, April 24, 2019)
Popular heart drugs tainted with carcinogens face a wave of lawsuits (Bloomberg, April 24, 2019)
State Drug controllers have authority to issue stop-sale order for medicines (Medical Dialogues, April 23, 2019)
Local pharma companies challenge MNC pharma in pneumonia vaccine space (Economic Times, April 20, 2019)
Regulator may charge sheet Bio-Med over supply of adulterated polio drug (Mint, April 19, 2019)
DCGI directs JnJ to pay compensation as directed (The Hindu, April 19, 2019)
New legal risks emerge for India pharma (Economic Times, April 19, 2019)
DCGI directs drug manufacturers to incorporate adverse events into leaflets (The Mint, April 18, 2019)
Building a culture of compliance (Indian Express, April 17, 2019)
After JnJ implant row, govt plans to hire 750 to regulate medical devices (The Print, April 17, 2019)
Drug manufacturers in Bihar to approach DCGI to complain against state DC for anti-industry policies (Pharmabiz, April 17, 2019)
Indian pharma growth decelerated in March: CLSA (CNBC TV18, April 16, 2019)
FMCG Lessons for Pharma (Forbes India, April 16, 2019)
How Singh brothers got into trouble – bit by bit (Business Today, April 11, 2019)
Singh brothers get a breather from the top court (Business Today, April 11, 2019)
Indian execs named in US pharma probe (Economic Times, April 11, 2019)
Regulating Biologicals (Business Today, April 21, 2019)
IIT-Delhi startup Sanfe falsely claims FDA approval and AYUSH ministry certificate for pain relief roll-on (Altnews.in, April 7, 2019)
Explainer: Failing tests at Johnson & Johnson (The Hindu, April 7, 2019)
In a poor Kenyan community, cheap antibiotics fuel deadly drug resistant infections (NY Times, April 7, 2019)
Modi report card: Healthcare becomes part of mainstream discourse (The Week, April 5, 2019)
New set of rules for clinical trials in India (The Pharma Letter, April 5, 2019)
One should always buy generic medicines from reliable brands or outlets (Indian Express, April 5, 2019)
Government awards Delhi patient 67 lakhs for faulty JnJ Hip implant (Hindustan Times, April 5, 2019)
Contaminated generic drugs reveal an urgent public health crisis (Observer, April 4, 2019)
Drug making MNCs ask government to create a registry of drug applications pending manufacturing, marketing approval (Times of India, April 4, 2019)
The absurdly high cost of insulin, explained (vox.com, April 3, 2019)
HC refuses to hear plea on generic drugs (The Hindu, April 2, 2019)
India’s clinical trial rules to speed up approvals (Nature, April 2, 2019)
Medicines of nine Indian pharma companies found non-compliant to good manufacturing practices (Kathmandu post, April 2, 2019)
‘Jobs- Reality Check’: Indian pharma has little to offer on job creation (Business Today, April 1, 2019)
JnJ told to pay damages, but patients skeptical (The Hindu, April 1, 2019)
Most cancer medicines are still not affordable: Aidan (Newsclick.com, April 1, 2019)
Delhi HC dismisses Malvinder Singh’s plea on access to pension fund account (theprimetime.in, March 30, 2019)
Punjab man shoots officer dead over 10-year-old matter, kills himself later Punjab man shoots officer dead over 10-year-old matter, kills himself later (Hindustan Times, March 30, 2019)
CDSCO asks State Drug Regulators to keep strong vigil on Buclizine sales (Indian Express, March 30, 2019)
Indian pharma: What’s next after Gottlieb? (Biospectrum India, March 29, 2019)
Despite ban, motion sickness medicine buclizine being sold as appetite stimulant (Indian Express, March 29, 2019)
SIngapore recalls BP drugs with India made ingredients (Deccan Chronicle, March 29, 2019)
A rash approach to Clinical Drug Trials (The Telegraph, March 28, 2019)
New York sues Slacker family members and drug distributors (NY Times, March 28, 2019)
Modi govt’s affordable medicines scheme fails second audit in less than a year (The Print, March 28, 2019)
The worrisome rise of direct-to-consumer medicine (Undark Magazine, March 28, 2019)
Tainted pills force the FDA to tighten drug safety regulations (Bloomberg, March 27, 2019)
Aviation disasters highlight fundamental flaws at the FDA (People’s Pharmacy, March 25, 2019)
Pharma MNCs wary of import of innovator drugs (Economic Times, March 21, 2019)
Dallas Fort Worth looks to India for Pharma flows (AirCargo News, March 20, 2019)
Issues of quality in pharmemerging countries more spoken about than real (in-pharmatechnilogist.com, March 20, 2019)
Conflicts of interest with India’s health industry: The need for legal intervention (The Wire, March 20, 2019)
India’s well-intentioned Jan Aushadhi Scheme providing a challenge to branded generic firms (The Phrama Letter, March 20, 2019)
Amit Rajan and Surajit Pal speak about US FDA’s strict policies for Indian companies (Times News Now, March 18, 2019)
Jan Aushadi scheme may disrupt 20% of India pharma market: Report (Business Standard, March 17, 2019)
India’s predicament of controlling anti-cancer medicine prices (Moneycontrol, March 17, 2019)
CDSCO to issue show cause notices to unlicensed manufacturers of orthopedic implants (Business Standard, March 16, 2019)
Clinical outcomes compared with generics, brand-name drugs for chronic conditions (MPR News, March 15, 2019)
How the not for profit, CivicaRx will disrupt the Generic Drug Industry (STAT, March 14, 2019)
Intermountain CEO, Dr Marc Harrison: How CivicaRx will disrupt the drug industry (Hospital Review, March 14, 2019)
Since you aren’t a Sadhu anymore, start thinking about money, SC tells former Fortis promoter (News18, February 14, 2019)
CDSCO directs JnJ to pay INR 74.5 lacs to first patient with faulty hip implant (THe Wire, March 13, 2019)
Pfizer plant that is closing gets farewell warning letter from the FDA (Fierce Pharma, March 13, 2019)
Biocon biosimilar plant criticized again by the FDA (Fiercepharma, March 12, 2019)
Secrets of generic drug markets revealed (The Telegraph, March 12, 2019)
Global pandemic of fake drugs killing children worldwide, report says (CNN, February 12, 2019)
Opposition in India to patent extension for Janseen’s TB drug (The Pharma Letter, March 11, 2019)
Muddled patent dispute sheds light on UCLA’s questionable ties to big Pharma (Daily Brun, March 10, 2019)
Hidden FDA reports detail harm caused by scores of medical devices (KHN.org, March 07, 2019)
Pharmacies sell some medicines at 500-2000% premium (The Hindu, March 05, 2019)
Is traceability good medicine for dysfunctional supply chains? ( Center for Global Development, February 26, 2019)
Did the FDA ignite the opioid epidemic ? (CBS News, February 26, 2016)
India losing out on clinical trials raising health worries (The Mint, February 26, 2019)
Caught in crossfire: Fortis (The Mint, February 25, 2019)
Fortis asks SEBI to arrest former promoters (The Mint, February 25, 2019)
Truth is stranger than Phicton (Slate.com. February 24, 2019)
New drug panel could water down affordable healthcare New drug panel could water down affordable healthcare (The New Indian Express, February 24, 2019)
As going gets tough, pharma firms revisit decisions (Economic Times, February 21, 2019)
Elephant Vs Dragon, India needs to promote innovation to avoid loosing out to China (Financial Times, February 21, 2019)
Recurring cGMP violations at Lupin, Dr Reddy’s, data-integrity concerns art Indico, Vipor (Pharmacompass, February 21, 2019)
Amit Rajan speaks on US FDA’s strict action against Indian Pharma (Timesnewsnow.com, February 19, 2019)
Injectable units under cloud as India lacks experts in aseptic practices (Economic Times, February 19, 2019)
Fortis fraud may exceed INR 2000 Crore, says SIFO (The Mint, February 19, 2019)
Singh brothers feud is a wake up call for corporate governance in dysfunctional family run companies (Firstpost, February 18, 2019)
JnJ implant patients object to compensation package (Indian Express, February 18, 2019)
Malvinder Singh drops a death threat bomb, sues Baba, Shivinder, Godwani (Business Standard, February 17, 2019)
Parliamentary panel seeks action IT officers for irregular assessment against freebies to doctors (Economic Times, February 17, 2019)
Machines used to diagnose cancer remain unused in JJ hospital for 5 years (Pune Mirror, February 13, 2019)
Rs 5 Crore paid as compensation to Clinical Trial victims since 2015 (The Wire, February 13, 2019)
Counterfeit medicines, from head-ache medicines to cancer drugs have become a multi-billion dollar problem (CBC News, February 13, 2019)
No local woe, India’s poor Public Health feeds Antibiotic Resistance Worldwide (The Wire, February 13, 2019)
Drug quality goes for a toss (The Hindu, February 13, 2019)
At What Cost? (Bloomberg, February 13, 2019)
88 clinical trial volunteers died in four years due to direct side effects: Health Ministry (HIndustan Times, February 12, 2019)
Pharma group asks USTR to drop India from watch list (Life Sciences Intellectual Property Review, February 12, 2019)
Dhaka sellers club: Let down, Indian cancer patients turn to cheap imports (The Ken, February 12, 2019)
Dr Reddy’s Bachupally plant experiences a version of FDA deja vu (FiercePharma, February 12, 2019)
Trump Administration salutes a parade of generic approvals, but hundreds aren’t for sale (Kaiser Health News, February 8, 2019)
The FDA under Trump has approved 1600 generic drugs; but many arent for sale yet (Tampa Bay Times, February 8, 2019)
11% drug samples from government hospitals fail quality tests (The Hindu, February 7, 2019)
Vigilance on drug pricing good, but interests of Indian pharmaceutical industry should be safeguarded (Pharma Letter, February 7, 2019)
Generic drug approvals surge, but hundreds are not for sale (CNN, February 7, 2019)
ICH seeks to harmonize Generic Drug Standards (RAPS, February 6, 2019)
Trump’s speech had an ominous message for drug makers (Business Insider, February 6, 2019)
At what cost? (Bloomberg, February 6, 2019)
Why are prescription drug prices rising? (US News and World Report, February 6, 2018)
Govt moves Supreme Court against Delhi HC ban on Oxytocin (The Mint, February 4, 2019)
Returns down from US generic drugs market for Indian pharma firms (Business Standard, February 2, 2019)
Compulsory licensing of pharmaceutical patents in India: A policy shift (Political and Economic Weekly, February 2, 2019)
The $4.3 billion deal that blew up over shoddy production (Bloomberg, February 1, 2019)
New formulations can delay generic drug entry, study says (RAPS, January 31, 2019)
Culture of “bending rules” in India challenges US drug agency (Bloomberg, January 31, 2019)
Generic drugs face quality, safety concerns (Axios, January 30, 2019)
How a tainted heart drug made in China slipped past the US FDA (Bloomberg, January 30, 2019)
America’s love affair with cheap drugs has a hidden cost (Bloomberg, January 29, 2019)
Use compulsory license and put ceiling to curb prices of patented medicines (Economic Times, January 27, 2019)
Drug pricing regime: Pharma companies express relief; activists miffed (Moneycontrol.com, January 27, 2019)
Government plans to make manufacturers pay for the entire batch if a single drug is found substandard ( Business Today, January 27, 2019)
A healing touch for healthcare (India Today, January 25, 2019)
The illness plaguing India’s pharmaceutical sector (The Mint, January 24, 2019)
What ban? Online pharmacies sweeten the pill in Delhi (The HIndu, January 21, 2019)
5000 people lost their lives in the conduct of clinical studies (ET Healthworld, January 21, 2019)
Quality test of 6000 medicine samples pending for a year in Rajasthan (ET Healthworld, January 21, 2019)
Two courts, two different views on online drug sales (The Hindu, January 21, 2019)
Think incremental innovation (The Hindu, January 20, 2019)
80 types of medicines on sale without Center’s permission to be banned (DBPost, January 17, 2019)
Hooked to the pill: India’s antibiotic overkill (The Mint, January 17, 2019)
Court asks government to retest samples of Ghaziabad based firm’s polio vaccine (The Mint, January 14, 2019)
Blood pressure drug recall: FDA investigates foreign plants that made drugs with cancer causing impurities (USA Today, January 14, 2019)
New drug price cap extensions pitch DoP against Health Ministry (The Mint, January 7, 2018)
When medicines make patients sicker (KHN News, January 4, 2019)
Center under pressure to ban unsafe drugs (Health Issues India, December 24, 2018)
Explained: How the government’s ban on Oxytocin was unscientific (The Wire, December 21, 2018)
Delhi High Court seeks government’s reply on unsafe drugs ban plea (Economic Times, December 21, 2018)
3.36% of about 82,600 drugs sampled found substandard (Economic Times, December 19, 2018)
Sartan drug contamination brings cancer uncertainty (Chemistry World, December 4, 2018)
JnJ pushed another faulty hip implant in India, faces music in US, not here (Indian Express, June 29, 20198)
In the US, Ortho was forced to admit it was corrupting doctors in India (Indian Express, November 28, 2018()
Big medical device bazaar: Faulty implants, basement surgeries, lives at risk (Indian Express, November 25, 2018)
Legalizing compensation to victims of faulty medical devices: destination clear, but where is the road? (Moneycontrol.com, November 23, 2018)
Mother, they are not counting the smallest coffins (CNBC TV18, November 23, 2018)
No harmony among zonal offices and central drug regulator (Indian Express, November 22, 2018)
Indian pharma’s window of opportunity (Business Today, November 21, 2018)
CDSCO reopens clinical trial rules for comment (RAPS, November 21, 2018)
Potential rules benefitting clinical trials (ET Healthworld, November 21, 2018)
Conundrum! India Inc’s RCEP fear is not unwarranted (Financial Express, November 20, 2018)
Switching Sciences: Pharma billionaires (Forbes India, November 16, 2018)
Expired medicines sold by re-stamping them as unexpired serious matter: Delhi HC (Financial Express, November 16, 2018)
Modi government deals compensation JnJ could pay for faulty hip implants (theprint.in, November 1, 2018)
Bitter pill (The Week, November 4, 2018)
Fake drugs: the global industry is putting your life at risk (mosaicscience.com, October 30, 2018)
India’s CCI slams drugmakers over anti-competitive practices (The Pharma Letter, October 29, 2018)
What the data on oxytocin “misuse” show (Indian Express, October 29, 2018)
Regulator asks drug makers to label Fluoroquinolone with side-effect warnings (ET Healthworld, October 26, 2018)
Complex Generic guidance by the US FDA to benefit India Pharma (Indian Express, October 26, 2018)
How Singh brothers enriched a builder developing the next Trump towers (Bloomberg Quint, October 25, 2018)
Modi government’s ambitious TB eradication scheme is stuck because it cannot locate patients (The Print, October 25, 2018)
Polio vaccine contamination case: Bio-Med MD gets bail, drug inspectors apologize to the court (Economic Times, October 24, 2018)
Daiichi alleges fraudulent siphoning of Rs 2000 crore by Singh brothers (Economic Times, October 23, 2018)
Are companies bribing doctors to push vaccine combos? (Times of India, October 22, 2018)
SEBI directs Fortis to recover Rs 403 Crore from Singh brothers within 3 months (The Hindu, October 19, 2018)
SEBI order throws a spanner into Singh brothers’s plan (Economic Times, October 19, 2018)
SEBI directors Singh brothers, 8 other entities to repay Rs 408 Crore to Fortis Healthcare (Economic Times, October 19, 2018)
Daiichi-Sankyo accuses Fortis’ Singh brothers of siphoning Rs 2900 Crore via downstream companies (The Hindu, October 23, 2018)
Polio vaccine contamination: Government needs to fix drug procurement policy for public health (Financial Express, October 17, 2018)
An unregulated mess: Inside India’s medical device industry (Bloomberg Quint, October 10, 2018)
Patients deserve quality medicines (ET Healthworld, October 10, 2018)
Hey India, sue JnJ in the US, take care of the victims here (Bloomberg Quint, October 8, 2018)
Will China’s crackdown on drug manufacturers impact India (Moneycontrol, October 8, 2018)
Compensation matters: What is it about the west that compensation amounts to million dollar suits, while in India, patients are left with a pittance (Financial Express, October 7, 2018)
Cutting corners on medicine (The Hindu, October 7, 2018)
Oral polio vaccine contamination has doctors concerned due to shortage of safer injectable options (Firstpost, October 6, 2018)
Mysterious drug pricing group reveals who is running it – but not donors (Washington Examiner, October 6, 2018)
Supreme Court seeks center’s response on faulty JnJ implants (Economic Times, October 6, 2018)
JnJ faulty hip implant: SC asks expert panel to submit report in 2 months (The Mint, October 6, 2018)
Delhi HC issues notice in a petition to close online pharmacies (Barandbench, October 6, 2018)
States with a glut of doctors keep churning them out (TNN, October 6, 2018)
Legal liability should not depend on ad-hoc largesse (Hindustan Times, October 5, 2018)
Hip implants dent brand J&J, patients begin questioning other devices (The Print, October 5, 2018)
Unjoined dots of a scheme (Indian Express, October 5, 2018)
Faulty hip implants: Supreme Court asks Centre to respond to PIL against JnJ (Scroll, October 5, 2017)
FDA bans import of all APIs from Zhejiang Huahai: EU issues non-compliance certificate (PharmaCompass, October 3, 2018)
More care needed in filling healthcare posts (The Hindu, October 3, 2018)
Test all polio vaccine for Type 2 strain: DCGI (The Mint, October 3, 2018)
Polio vaccine scandal: CDSCO scanning Bio-Med premises (The New Indian Express, October 3, 2018)
India’s FDC saga and other stories (Indian Express, October 3, 2018)
Why India’s Health Ministry cannot take contamination of polio vaccine lightly (The Newsminute, October 3, 2018)
Patient interest must override a criminal action threat in JnJ implant case (The Print, October 3, 2018)
Risk from polio vaccine contamination may be low, but there is a greater need for strong surveillance (Scroll, October 3, 2018)
Explainer:How bad is the “polio vaccination controversy”? (The Wire, October 3, 2018)
Government moves to contain panic after 30 lakh kids get ‘eradicated’ polio strain with vaccine (The Print, October 2, 2018)
Act swiftly and decisively to avert a public health crisis (Economic Times, October 2, 2018)
JnJ, Modi Government at odds over compensation for faulty hip implants (The Print, October 2, 2018)
Caregivers or marketers? Nurses paid by drug companies facing scrutiny as whistleblower lawsuits mount (STAT News, October 2, 2018)
Risk to children from contaminated oral polio vaccine found in India is “minimal” says WHO (Scroll, October 2, 2018)
150,000 Indian children may have received contaminated polio vaccine (Precision Vaccinations, October 1, 2018)
WHO plays down risk to Indian children from tainted polio vaccine (Reuters, October 1, 2018)
Nadda allays fear over adulterated polio vaccine vials (The Hindu, October 1, 2018)
Drug regulator forms teams to probe polio vaccine lapse case (The Mint, October 1, 2018)
Polio back in India? Probe launched after virus carrying vaccine given to UP children (News18, October 1, 2018)
Contaminated vaccines put India’s “polio free” status at risk (Times of India, October 1, 2018)
Contaminated polio vaccine given to children, probe ordered (NDTV, September 30, 2018)
Surgery needed, not band-aid (The Economic Times, September 28, 2018)
Discrimination, growing resistance to drugs fueling India’s Tuberculosis crisis (The Wire, September 27, 2018)
Investigation into sartan medicines broadens after “potent” contamination (In-Pharma Technologist, September 27, 2018)
Ayurvedic docs, pharma agency booked for medicine adulteration (The times of India, September 27, 2018)
Make it large: a significant trend in the Indian pharma industry (The Mint, September 25, 2018)
Larger picture: Joining PIC/S a big boost for drug quality (Financial Express, September 25, 2018)
Drug firms retaining old brand names for new medicines (The Mint, September 24, 2018)
Withdrawing faulty hip implants: How JnJ went back on its word to the regulator (Indian Express, September 20, 2018)
CCI probe finds unfair practices by three drug companies (Economic Times, September 20, 2018)
JnJ has to pay patients cleared by the government panel: Health Ministry official (ET Healthworld, September 19, 2018)
Panel to decide compensation for faulty hip implants hold first meeting (ET Healthworld, September 19, 2018)
Prices soar for hospital drugs after shortages hit, study finds (Bloomberg, September 17, 2018)
Big pharma firms may have underpaid Rs 530 crore in Indian Taxes (The Wire, September 19, 2018)
Pharma firms in 16 nations evading $3.8 billion in taxes every year (Times of India, September 18, 2018)
Lessons we must learn from the FDC fiasco (Moneycontrol.com, September 17, 2018)
SC allows sale of Saridon, 3 other drugs (Times of India, September 17, 2018)
Headache over for now: SC lifts ban on sale of painkiller Saridon (Business Standard, September 17, 2018)
Roorkee emerging as the hub of fake medicines (Economic Times, September 17, 2018)
Blame J&J, but the bigger culprits are the DCGI and Indian laws (ET Prime, September 17, 2018)
Out of joint: Documenting the repercussions from JnJ’s faulty hip implants (The Hindu, September 15, 2018)
A JnJ helpline that really doesnt help people seeking compensation (ET Healthworld, September 15, 2018)
JnJ hip implant victims narrate their ordeal (Economic Times, September 15, 2018)
JnJ hip implant row: Make us a part of the compensation process, say patients (The Week, September 15, 2018)
JnJ hip plant patients meet in Delhi, demand accountability (The Mint, September 15, 2018)
Faulty JnJ implant: Affected patients seek representation to decide their future (The Hindu, September 15, 2018)
Faulty hip implant case: First panel meet on compensation on Sept 18 (Business Standard, September 15, 2018)
India bans 328 combination drugs in setback to pharma companies (Reuters, September 13, 2018)
DCGI issues notice to trace 4700 patients with J&J hip implants (The Tribune, Sept 13, 2018)
Ex-DCGI says prompt action was taken in patient interest (The Mint, Sept 13, 2018)
Where do your pills come from? (The Vindicator, September 13, 2018)
India proved patent laws not cast in stone (Business Daily Africa, September 13, 2018)
Government prohibits 328 fixed dose combinations (Economic Times, September 13, 2018)
Despite big spending on legal and professional consultants, FDA woes continue to haunt pharma companies (Economic TImes, September 12, 2018)
Health Ministry to ban 328 combination medicines over safety concerns (The Economic Times, September 12, 2018)
Singh is King, Part 1(HW News, September 12, 2018)
JnJ Case: Parliamentary panel members lash out at CDSCO (Economic Times, September 11, 2018)
Sun pharma receives fresh warning from the US regulator on Indian plant (The Pharma Letter, September 9, 2018)
Not all hip implants are faulty:everyone wont be compensated (The Mint, September 8, 2018)
Will give appropriate payout: JnJ on faulty implants (Times of India, September 8, 2018)
SC restrains government from taking a call on 15 FDC drugs (The Mint, September 8, 2018)
Delhi HC orders Singh brothers to pay Rs 9 Cr to Daiichi (Indiawire.com. September 8, 2018)
Supreme Court prescribes pain relief for 15 banned combination drugs (The Economic Times, September 8, 2018)
JnJ says India claims vexatious, cites different legal system (The Hindu, September 7, 2018)
Faulty hip implants: Regulator blames JnJ for negligence (Times of India, September 6 , 2018)
Hospitals are fed up with drug companies, so they are starting their own (Washington Post, September 6, 2018)
Govt knew of JnJ faulty implants, took almost two years to ban (Indian Express, September 6, 2018
Drugs are not sweets (The HIndu, September 5, 2018)

Half of JnJ implant users unaware of defects (The Times of India, September 5, 2018)
JnJ implant case: The moral hazard of multinationals (The Mint, September 5, 2018)
Statement from US FDA Commissioner Scott Gottlieb on the agency’s global efforts to ensure transparency and product quality at foreign drug manufacturing sites (US FDA, September 5, 2018)
JnJ subsidiary hip replacement row: Timeline of events (Economic Times, September 4, 2018)
Overhaul the medicine supply chain (HIndustan Times, September 1, 2018)
Voluntary recall doesnt imply hip implant was faulty: JnJ (The Mint, September 1, 2018)
Shocking negligence (The Hindu, August 31, 2018)
Govt cannot prosecute JnJ for faulty hip implants under the current law (The Mint, August 30, 2018)
CDSCO reluctant to disclose RTI information on JnJ’s faulty hip implants (The Wire, August 30, 2018)
Depuy objected to disclosure of information on import clearance for faulty hip implants (ET Health World, August 30, 2018)
Cure that hurts (Indian Express, August 30, 2018)
What JnJ faulty implant saga tells us (Bloomberg Quint, August 30, 2018)
Gap in law bars government from prosecuting JnJ (Times of India, August 30, 2018)
JnJ admitted: Many young patients affected by hip implants (The Indian Express, August 30, 2018)
Faulty JnJ hip implant: Cost of crippling a life is $13,550 a month (The Hindu, August 29, 2018)
Maharashtra FDA ex-chief accuses DCGI of action against JnJ (Economic Times, August 29, 2018)
The JnJ hip implant case: India must up its game on patient safety (Moneycontrol.com, August 28, 2018)
Govt plans tweaks in law to make firms liable for defective devices, drugs (The Mint, August 26, 2018)
Why India must discard fear, give some TB patients game changing drug (Indiaspend.com, August 26, 2018)
A plan for change: Mental Healthcare Act (The Hindu, August 26, 2018)
Not all is well with India’s corporate hospital chains (Economic Times, August 26, 2018)
People Vs Big Pharma: tacking the industry’s trust issues (In Pharma Technologist, August 25, 2018)
JnJ may have to compensate for faulty hip implants (Economic Times, August 25, 2018)
Top official sought CBI probe into hip implants sold by Indian arm of JnJ (Indian Express, August 25, 2018)
Govt will ask JnJ to pay compensation for faulty hip implants (The Mint, August 24, 2018)
US Medicare could have saved $1 billion by substituting branded drugs (Economic Times, August 24, 2018)
India’s prescription-based medicine dispensing has little relevance from regulatory perspective (Pharmabiz, August 24, 2018)
JnJ buried key facts on faulty hip implant surgeries, kept regulator in the dark (Indian Express, August 24, 2018)
Discarded antibiotics make a comeback as fight against superbugs gathers pace (The Print, August 24, 2018)
Singh brothers say Sunil Godwani “orchestrated” transactions (Business India, August 23, 2018)
How JnJ is scooting from the hip (The Mint, August 23, 2018)
China dismisses top officials over sub-par vaccines (In-pharma Technologist, August 22, 2018)
Toxin at the heart of drug recall shows holes in medicine safety net (Reuters, August 22, 2018)
As health crises grow, 29% of the funds with states not spent in 5 years (Indiaspend.com, August 20, 2018)
National Health Stack: Data for data’s sake, a manmade health hazard (Bloomberg Quint, August 20, 2018)
There is an explosion of data & digital opportunities in India’s healthcare (Economic Times, August 20, 2018)
PSC exposes conflict of interest in inquiry (The Hans India, August 14, 2018)
The need for a strong UN declaration on TB (The Mint, August 19, 2018)
‘Jugaad: India’s most overrated idea’ (The Mint, August 19, 2018)
China sacks 6 senior officials over vaccine scandal (Indian Express, August 19, 2018)
Why is retail sale of Oxytocin banned? (The Hindu, August 18, 2018)
Rising cost of Chinese raw materials eat into the margins of Indian pharma companies (Moneycontrol, August 16, 2018)
Questioning the crackdown (The Hindu, August 16, 2018)
USFDA issues a warning letter to Apotex research (Times of India, August 16, 2018)
The Billionaire and the Guru: How a family burned through $2 billion (Bloomberg, August 16, 2018)
FDA recalls are a reminder that China controls much of the world’s drug supply (NBC News, August 15, 2018)
Form 483 in India and China: Crunching the numbers (RAPS, August 14, 2018)
Does India really need a costly national health scheme with Rs 5 Lakh as insurance cover? (Scroll.in, August 14, 2018)
Series explores how pharmacy contracts obscure drug pricing details from customers (AHCJ, August 13, 2018)
Chinese vaccine scandal – why should we also care (ORF India, August 13, 2018)
India’s Hetero pulls heart drug from the US amid cancer risk probes (Economic Times, August 13, 2018)
Alert on spurious drugs by central body catches J&K drug dept ill prepared (Kashmir Reader, August 13, 2018)
Cheap medicines go missing from JA Centers (Economic Times, August 13, 2018)
Delhi High Court says Malvinder, Shivinder Singh cannot operate bank accounts (Economic Times, August 10, 2018)
Daiichi-Ranbaxy row: Singh bros appear in Delhi HC, restrained from using bank accounts (Indian Express, August 10, 2018)
Daiichi-Ranbaxy row: Delhi HC restrains Singh brothers from using bank a/cs (The Mint, August 10, 2018)
The government must establish a department of public health soon (Hindustan Times, August 10, 2018)
Red flags raised at Chinese heart drug maker a year before recall (Bloomberg, August 9, 2018)
CDSCO authorizes SLAs to issue NOC for drug exports effective August 20, 2018 (Pharmabiz, August 6, 2018)
Rational use of drugs (MilleniumPost, August 6, 2018)
Fortis management protested, but was overruled (The Mint, August 6, 2018)
Maharashtra scouts for talent: Rs 3 lakh per month for rural doctors (The Indian Express, August 5, 2018)
Oxytocin sale: MoH backtracks its stance (Indian Express, August 5, 2018)
Drugs as herbal medicines: Police arrest Gurgaon man (Indian Express, August 5, 2018)
Doctors tring in change (Mumbai Mirror, August 4, 2018)
Health Ministry to ban over 300 combo drugs (Economic Times, August 4, 2018)
In a push for pharma exports, states get NOC booster shot (Times of India, August 4, 2018)
How green are Indian manufacturing sites? (The Hindu, August 3, 2018)
State drug regulators get power to issue NOCs meant for drug export (Indian Express, August 3, 2018)
Poor show by Indian pharma companies (Pharmabiz, August 1, 2018)
Govt drug price caps may trigger showdown with US (Times of India, July 31, 2018)
India is rich from a science perspective: Rajiv Malik (Forbes India, July 30, 2018)
In two years, 953 prosecuted for drug-related violations (The Hindu, July 29, 2018)
Regulated drug sale sans prescription on the rise in Odisha (New Indian Express, July 29, 2018)
Prescribing medicines without diagnosis amounts to culpable negligence: Bombay HC (The Indian Express, July 26, 2018)
Panel recommends ban on 343 Fixed Dose Combination medicines (Economic Times, July 26, 2018)
Working group may vet plan to check fake drugs (Economic Times, July 26, 2018)
Oxytocin ban: Drug makers report panic buying by hospitals (Economic Times, July 26, 2018)
No case of bad quality generic medicines in India (Economic Times, July 24, 2018)
Shortage of basic medicines in state run hospitals (Mumbai Mirror, July 24, 2018)
Legal liability of Generic Vs Brand drug manufacturers for inadequate product labels (JAMA, July 24, 2018)
Panel reviewing efficacy of 349 FDCs may reinforce ban (The Mint, July 24, 2018)
Speaking for myself (National Medical Journal of India, July 23, 2017)
China police probe vaccine maker after scandal sparks fury (Reuters, July 23, 2018)
JnJ to offer first TB drug in 40 years for $900 (Economic Times, July 23, 2018)
Why private hospitals should join NHPM (The Mint, July 23, 2018)
Please do the needful (The week, July 21, 2018)
Sale of Schedule H1 drugs under lens (ET Health, July 20, 2018)
Inside India’s fake research paper shops: pay, publish, profit (Indian Express, July 19, 2018)
Explained: How the pay-and-publish business works (Indian Express, July 18, 2018)
Right Prescription (Business Standard, July 19, 2018)
FDA nails Baxter with warning letter for plant picked up in Claris buyout (FiercePharma, July 18, 2018)
Baxter gets US FDA warning letter on recently acquired Claris plant (CNBC TV18, July 18, 2018)
Indian Pharma: Think beyond price control (Financial Express, July 19, 2018)
Dying to survive: Indian generic medicines have a tale to tell (Business Today, July 18, 2018)
Pharma quality is the key for competition (The Mint, July 17, 2018)
Ajanta Pharma under scanner for marketing unapproved drugs (The Mint, July 17, 2018)
‘World’s pharmacy’ reaches a crossroad as Indian generic drugs face rising competition, tougher regulation (Global Times, July 17, 2018)
Why India is not ready for Modi government’s generic only diktat (Theprint.in, July 15, 2018)
Generic drugs to be on special display Generic drugs to be on special display (Pune Mirror, July 15, 2018)
The drug pricing playbook: how pharma companies keep costs high (Financial Times, July 12, 2018)
Gujarat FDCA concludes joint inspections of 17 MSME manufacturers with CDSCO, serves notice for remedial measures (pharmabiz.com, July 12, 2018)
With US trade under a cloud, China opens to Indian pharma (Moneycontrol.com, July 12, 2018)
Novartis joins big pharma exodus out of antibiotics, dumping research & cutting 140 out-licensing programs (Endpoints.com, July 12, 2018)
A parallel universe of clinical trials (NEJM Editorials, July 12, 2018)
Religare Finvest claims Rs 1900 crore from 19 companies ‘known’ to Malvinder & Shivinder Singh (Economic Times, July 12, 2018)
WHO tells government strict clinical trial rules will drive away drug firms (The Mint, July 11, 2018)
Brothers Singh and the squandering of a business empire (The Mint, July 10, 2018)
Can medicines be made affordable? (ET Healthworld, July 10, 2018)
Health Ministry to amend D&C rules to make marketing companies also accountable for quality of medicines (Pharmabiz, July 10, 2018)
Chinese pharma firms enter golden era; set to surpass Indian counterparts (Global Times, July 10, 2018)
Dragon smiles on India pharma industry: Will China’s latest move help India bridge wide trade deficit? (Financial Express, July 10, 2018)
Clinical trials not mandatory for licensing ASU drugs: says government; researchers warn of fraud, textual data manipulation (Pharmabiz, July 10, 2018)
Rajiv Gandhi hospital wasted life-saving, other drugs worth 16 crore: audit (Times of India, July 10, 2018)
Improved, new drug offers hope for Indian mothers dying during childbirth (Indiaspend.com, July 10, 2018)
Misreading the pharma market (Indian Express, July 10, 2018)
Paracetamol sales rising, but firms revenue suffers due to price cuts (Indian Express, July 10, 2018)
Poor Indians turning guinea pigs for greedy pharmaceutical firms (The Hans India, July 10, 2018)
Healing Healthcare (The Mumbai Mirror, July 9, 2018)
Private hospitals brandish Karnataka’s unscientific study to demand higher reimbursements (The Wire.in, July 9, 2018)
What Fortis Healthcare’s FY18 audit report reveals (The Mint, July 9, 2018)
Getting the generic drug plan right (The Hindu, July 9, 2018)
India’s oldest hack may be its biggest obstacle on the road to world power (Economic Times, July 8, 2018)
Singh brothers may have taken fresh loans from Fortis to repay funds diverted from the hospital chain, company says (Economic Times, July 8, 2018)
52% of medicine supplied without quality check: Comptroller & Auditor General (Indian Express, July 8, 2018)
Pay fine for invasive tests without patient’s nod: Consumer panel to hospital (Indian Express, July 8, 2018)
A shot of confidence for Indian pharma: its regulator (The Hindu, July 7, 2018)
Fortis board unable to determine if fraud occurred: Auditor (Times of India, July 7, 2018)
Why the queue of suitors for Fortis hospitals is thinning (ET Prime, July 5, 2018)
Emergency rooms run out of vital drug, and patients are feeling it (NY Times, July 03, 2018)
The serialization spirit-where Indian pharma is (ET Healthworld, July 2, 2018)
Odisha government plans crackdown on sale of drugs without prescription (Indian Express, July 2, 2018)
Investors, NGOs, and water industry urge EU to take action on pharmaceuticals in the environment to halt AMR (European Public Health Alliance, July 2, 2018)
- Letter
T he problematic advocacy that portrays Bedquiline as a wonder drug (SpicyIP, July 2, 2018)
Brand name gets Singh brothers money if business cannot (ET Prime, July 1, 2018)
Singh brothers in blame game over Fortis mess (The Mint, July 1, 2018)
No easy cures (Indian Express, July 1, 2018)
When an Indian hospital was running out of oxygen, these doctors tried to help. So why were they sent to jail? (LA Times, June 30, 2018)
Drug purchase malpractice that led to deaths in 1986 has lessons for India’s health systems today (Scroll.in, June 30, 2018)
SEBI orders audit of Fortis Healthcare, SIFO suspects fraud (The Mint, June 30, 2018)
DTAB panel concludes hearings on FDC ban review: AIDAN remains optimistic about petition outcome (Phamabiz.com, June 29, 2018)
Delay in declaring audited numbers, Singh bros’ claim on boards spook investors (Moneycontrol.com, June 28, 2018)
Fortis’ Malvinder Singh authorized funds diversion into related entities (Economic Times, June 28, 2018)
Bangladesh’s bulk drug policy may hurt Indian exports (Live Mint, June 28, 2018)
The rat in India pharma’s kitchen (Economic Times, June 28, 2018)
Rationalizing trade margins for medical devices an half-baked idea, say activists (The Hindu, June 27, 2018)
This scheme is a lifesaver:India’s drive to provide cheap drugs (The Guardian, June 26, 2018)
FDA repays industry by rushing risky drugs to the market (Propublica, June 26, 2018)
China as India’s main bulk drug supplier: Helplessness or cautious evolution (ORFIndia, June 26, 2018)
Keep blueprints at home when partnering with Chinese pharma companies (The Wire, June 26, 2018)
Hospital Stocks: Lack of clarity on regulations acting on an overhang (Business Standard, June 26, 2018)
Extortinate life-savers (The Hindu, June 26, 2018)
Modi’s health insurance plan will be bigger than planned (Bloomberg Quint, June 25, 2018)
Price cap squeezes out key drug for children with heart ailment (Indian Express, June 23, 2018)
Is the pharma rally for real? (CNBC TV18, June 23, 2018)
Indian companies giving MNCs a run for their money in vitamins (Business Standard, June 22, 2018)
India’s serialization proposal for pharma is a bad idea (Securingindustry.com, June 22, 2018)
A complex idea (The Hindu, June 22, 2018)
Spurious drug issue:DCGI invites top pharma brands on June 25 (medicaldialogues.in, June 22, 2018)
Quality, safety issues continue to haunt top firms in India (Indian Express, June 22, 2018)
Empower us to substitute generic medicines for branded drugs: Pharmacists to Health Minister (mymedicalmantra.com, June 21, 2018)
Rs 3:Amount India spends each day on every Indian’s health (Indiaspend.com June 21, 2018)
Why do branded medicines cost 30-90% more than generic? (ET Healthworld, June 20, 2018)
Government to create a census of 20 lakh healthcare facilities by September (Economic Times, June 20, 2018)
A reply to Anand Grover on the Bedaquiline issue (SpicyIp, June 19, 2018)
To spot fake drugs, DCGI may introduce track and trace for the top 300 brands (Indian Express, June 19, 2018)
Pharma sector: 80% API via Chinese imports despite similar making costs (Indian Express, June 19, 2018)
Price control as a regulatory philosophy fundamentally dents the image of a country (ET Healthworld, June 18, 2018)
Darker side of private hospitals (Hans India, June 18, 2018)
Patently unjust: America is arm-twisting India (Deccan Herald, June 17, 2018)
Big pharma companies face action for marketing unapproved drugs (Economic Times, June 17, 2018)
Medical council of India largely responsible for corruption in healthcare, reveals committee (Firstpost, June 17, 2018)
Private hospitals 50% of their costs on salaries of medical staff, including doctors: Report (The New Indian Express, June 16, 2018)
How Sun Pharma managed to get its Halol Facility of the US FDA hook (Moneycontrol.com, June 16, 2018)
Jugaad culture: The good, bad and the ugly (The Mint, June 16, 2018)
Five takeaways from the Daiichi-Ranabxy dispute (Bar and Bench, June 14, 2018)
Pharma industry needs to adapt to global quality standards: OPPI (Business Standard, June 6, 2018)
Indian vaccine exports take ill as they are not immune to Chinese competition (The Print, June 6, 2018)
Sans consultant since November, NPPA faces legal hurdles (The Indian Express, June 5, 2018)
Government may enlist pharma firms for medicine banks (The Mint, June 4, 2018)
Global shortage of life saving drugs fuels rise in superbugs (The Telegraph, June 4, 2018)
Intriguing silence on drug prices (The Millennium Post, June 3, 2018)
Prices of Patented Medicines in India: To regulate or not to regulate (Economic and Political Weekly, June 2, 2018)
Indian pharma needs synergistic work culture to propel stronger quality standards (Pharmabiz, June 2, 2018)
Trial & Error: India’s complicated history with cervical cancer (Caravan, June 1, 2018)
Government weights linking medicine prices to wholesale price inflation (The Mint, May 30, 2018)
Linking medicine prices to WPI- boone or bane (BTVI, June 1, 2018)
Govt weighing linking drug prices to WPI inflation (The Mint, May 29, 2018)
The Bedaquiline Question (Newslaudry, May 29, 2018)
India can be a top pharma regulator (Pharmabiz, May 28, 2019)
A cure for medical malpractice (The Hindu, May 26, 2018)
Who is the boss of Indian Pharma? Doctor or Government (India CSR, May 25, 2018)
Why no one wants faulty drugs: A problem no one wants to talk about (NPR, May 24, 2018)
Panel reviewing the safety of FDC drugs to submit report in July (The Mint, May 24, 2018)
Lini Puthussery: India’s ‘hero’ nurse who died battling Nipah virus (BBC, May 22, 2018)
Critical condition: Inside Pfizer’s drug supply problem (Fortune, May 22, 2018)
Modi government’s ailing affordable drugs scheme may get a new lease on life at private chemists (ThePrint.in, May 22, 2018)
US FDA import alert and warning letter for Indian API maker (InPharma Technologist, May 22, 2018)
Dinesh Thakur, Ranbaxy whistleblower asks PMO to investigate illegal drug approvals in India (India Infoline, May 22, 2018)
Ranbaxy whistleblower petitions PMO to investigate illegal drug approvals (Economic Times, May 21, 2018)
Ensuring quality, safety and efficacy of generic drugs (Financial Express, May 20, 2018)
SMPMA urges DCGI to act against NSQ manufacturers as per DCC guidelines (Pharmabiz, May 17, 2018)
How a drugmaker gamed the system to keep generic competition away (NPR, May 17, 2018)
Five years after Indian Supreme Court’s Novartis verdict (IPWatch, May 18, 2018)
Four members of Fortis board under scrutiny, all eyes on EGM (Moneycontrol, May 18, 2018)
FDA names and shames drug makers to encourage generic competition (NY Times, May 17, 2018)
Compliance recap: cGMP noncompliance concerns continue to arise out of Asia (Pharmacompass, May 17, 2018)
Complaints with NPPA about drug shortage up 6-fold in 2017-18 (Indian Express, May 17, 2018)
Fortis deal: Shareholders may raise ‘conflict of interest’ against board members (The Hindu, May 15, 2018)
Healthcare on queue: Hurdles in Delhi’s health plans (Indian Express, May 14, 2018)
Govt planning unique codes to check menace of fake medicines (The Mint, March 13, 2018)
Indian pharma firms lukewarm on China’s lowered drug tariffs considering lengthy approvals (The Wire, May 13, 2018)
A remote U.P. village shines a torch on a lurking virus (The Hindu, May 13, 2018)
China’s plan to import Indian drugs fails to enthuse Indian pharma firms (The Hindu, May 13, 2018)
Fortis deal: A story that’s not yet over, till its over (The Hindu, May 12, 2018()
TB and the woeful state of health reporting in India (Newslaundry, May 11, 2018)
FDA Warning Letter tells India’s Goran Pharma to get professional help (FiercePharma, May 11, 2018)
‘Dead baby’ came back to life, but not case of negligence (The Wire, May 9, 2018)
Cure worse than RBI: Capping hospital profit margins will hit provision of healthcare (Financial Express, May 9, 2018)
CDSCO increases WHO GMP Certificate to three years for ease of doing business (Economic Times, May 9, 2018)
Government tweaks certification norms to aid pharma trade (The Mint, May 9, 2018)
Fresnius alleges “blatant fraud at the top level” of Akorn operations (Fierce Pharma, May 8, 2018)
Drug price control: Niti Ayog for exemption if below 10% fall in rate (Indian Express, May 8, 2018)
Will China tariff exemption lead to an increase in India pharma exports (Business Today, May 4, 2018)
Glenmark gets notice over misconduct in clinical trials (The Mint, May 4, 2018)
Compliance Recap: Data-integrity concerns re-emerge out of India & China (Pharmacompass, May 4, 2018)
Ex-IDPL employees threaten agitation if factory campus turned into convention center (Times of India, May 4, 2018)
CDSCO issues show-cause notice to Glenmark over clinical trial in Jaipur (May 4, 2018)
Indian pharma’s big leap (Business Today, May 3, 2018)
Fresenius claims blatant fraud at Akorn (Pharmacompass, May 3, 2018)
An unhealthy statement (Indian Express, May 3, 2018)
There is a rat in Indian pharma’s kitchen (ET Prime, May 3, 2018)
Unbranded generics, “orphan drugs” may go out of price control (Indian Express, May 3, 2018)
Damages outside of contract:Lessons from Daiichi-Ranbaxy (BusinessWorld, May 1, 2018)
India’s neglected tropical diseases (Downtoearth.in, April 30, 2018)
Telangana: All’s not well with pharma firms (The New Indian Express, April 30, 2018)
Law to punish pharma firms that bribed doctors languishing since 2015 (Times of India, April 25, 2018)
Uncontested clinical trial in Jaipur’s Malpani Hospital (News18, April 25, 2018)
Sikkim DC cancels license for Savi Pharma & suspends license of Savi Health Science for manufacturing new drugs without DCGI approval (Pharmabiz, April 25, 2018)
Harmonizing AYUSH and modern medicine: Can India learn from China (ORF, April 25, 2018)
A “Clinical Trial” controversy is unfolding in Jaipur: Who is responsible? (TheWire, April 25, 2018)
78% of drug patents grants in India for marginal improvements, says study (Business India, April 24, 2018)
Modi V Manmohan: Who is the better “medicine man” for India’s poor? (Thepint.in, April 24, 2018)
Drug controller conducts third raid on Pharma firms for unapproved drugs (The Wire, April 23, 2018)
Who invests in healthcare R&D (Brookings, April 23, 2018)
Glenmark suspends Phase II clinical trial following alleged “irregularities” at Indian site (Outsourcing Pharma, April 23, 2018)
“Your comments in London on Indian doctors have harmed our image” medical fraternity tells Modi (Scroll.in, April 23, 2018)
Government sets up high level task force to formulate roadmap for reviving API sector amid growing concerns over dependence on China (Pharmabiz, April 23, 2018)
India to push local manufacturing of APIs, reduce dependence on China (The Mint, April 21, 2018)
34% patients become sicker after medication change (Avrotros.nl, April 19, 2018)
Uttarakhand DC suspends licenses of 50 drug makers for manufacturing FDCs without DCGI approval (Pharmabiz, April 19, 2018)
Quality of pharmaceuticals should be the same across the world (Economic Times, April 19, 2018)
India’s import of Chinese-made medicines has increased 50% in 4 years (theprint.in, April 17, 2018)
Court allows enforcement of Daiichi-Sankyo award (India business law journal, April 17, 2018)
How Daiichi-Ranbaxy court ruling may impact remedy clauses in M&A deals (VC Circle, April 17, 2018)
Who is paying for India’s healthcare (thewire.in, April 14, 2018)
USFDA Observations:’Mosquitos, gnats in Alkem plant, no quality control unit’ (Indian Express, April 13, 2018)
To save lives, hospital to import anti-TB drug from South Africa (The Hindu, April 13, 2018)
There is no quality control unit: Emerging FDA concerns in India (Pharmacompass, April 12, 2018)
Drug firms oppose move to regulate oxytocin (Brinkwire.com, April 11, 2018)
Why Indian firms dont innovate (The Hindu, April 11, 2018)
Drugs sold sans regulator nods, safety studies (Times of India, April 11, 2018)
Health Ministry proposal to curb substandard drugs, antibiotics overuse in limbo (Indian Express, April 10, 2018)
China gives preferential tax rates for generic drugmakers (Reuters, April 5, 2018)
India to overhaul drug price control system (The Mint, April 5, 2018)
The reinvention of Indian drug makers: They are now selling FMCG products (theprint.in, April 5, 2018)
Enforcement of foreign arbitral award worth more than 3500 crores (mondaq.in, April 4, 2018)
Ranbaxy’s demise a wake-up call for business families in India (The Mint, April 4, 2018)
Punjab government doctors get 40% cut to prescribe drugs from private chemists (Hindustan Times, April 4, 2018)
Inadequate doctors and facilities at Ayush Hospitals and dispensaries: CAG Report (DNA India, April 4, 2018)
Drug regulator plans national digital database of pharma manufacturers (Economic Times, April 2, 2018)
Maharashtra: Comptroller and Auditor General report raises public health alarm (The Indian Express, March 29, 2018)
25% of poor quality drugs sold without checks: CAG raps FDA (The Hindu, March 29, 2018)
CAG Report: CAG finds glaring loopholes in schemes for the poor (The Times of India, March 29, 2018)
Ranbaxy and now Fortis Healthcare: Its curtains in healthcare for Singh brothers (The Hindu Business Line, March 28, 2018)
Whatever happened to India’s free national medicines scheme? (Thewire.in, March 27, 2018)
Lessons for India Inc from the Singh brothers (BusinessToday, March 27, 2018)
Growing drug resistance: Antibiotic consumption in India has skyrocketed, finds new study (Economic Times, March 27, 2018)
Indian judiciary needs to keep a check of big pharma (DailyO, March 27, 2018)
Uttarakhand drug controller bans manufacture & sale of all FDCs approved by state FDA following CDSCO crackdown (Pharmabiz, March 26, 2018)
Surge in antibiotics a boon for superbugs (NPR, March 26, 2018)
Dr Reddy to US FDA: Staff giving illogical answers not appropriate (Indian Express, March 25, 2018)
How the distressing spiral of Malvinder and Shivinder Singh came to be (Business Standard, March 25, 2018)
Pharma firms do not need a NOC for exporting products, medical devices (Moneycontrol, March 23, 2018)
Pharmaceutical industry can export without a NOC (KNN, March 22, 2018)
States must recall drugs, combination medicines sold without DCGI nod (Hindu Business Line, March 22, 2018)
Indian drugmakers need a new prescription (The Economist, March 22, 2018)
Firm under CDSCO lens over unapproved drugs (Times of India, March 22, 2018)
Saline Shortages – Many causes, no simple solution (The New England Journal of Medicine, March 21, 2018)
After chief’s transfer, govt wants to turn drug price regulator into market research agency (theprint.in, March 20, 2018)
NPPA must balance access with innovation (The Mint, March 20, 2018)
Parliamentary panel raps government over delay in framing law to regulate Ayush ads (Deccan Herald, March 19, 2018)
AIDAN approaches DTAB to remove non-experts from FDC panel (Pharmabiz.com, March 19, 2018)
Daiichi-Sankyo asks ED to probe Singh brothers in Religare, Fortis case (Economic Times, March 19, 2018)
Dangerous doses (Indian Express, March 18, 2018)
CDSCO flags drug firms for making and selling combination medicines without approval (March 17, 2018)
Wockhardt, two others under lens for selling drugs without approval (The Mint, March 16, 2018)
FDA poste 483s of major Indian pharma companies (pharmacompass.com, March 15, 2018)
7 companies blacklisted in TN for poor quality drugs (Economic Times, March 15, 2018)
An urgent prescription (The Hindu, March 14, 2018)
Indian pharma industry has tremendously improved in the last 2-3 years (Economic Times, March 14, 2018)
China accounts for 66% of India’s bulk drug imports in 2017 (Financial Express, March 13, 2018)
Deterrence from scams: A strong whistleblower law (Indian Express, March 13, 2018)
Low quality trials behind popular diabetes pills in India (Reuters, March 12, 2018)
Drug resistant TB and extreme journalism (reactionarydoc.com, March 11, 2018)
Finally, The Hindu acknowledges clinical trial issues regarding new TB drugs but through rose-tinted glasses (SpicyIP, March 11, 2018)
Branching out (Businessworld, March 10, 2018)
MHRA publishes Data Integrity Guidance (MHRA, March 9, 2018)
How does inclusion of patented drugs in a WHO EoI make them more affordable (SpicyIP, March 9, 2018)
Why potentially dodgy diabetes drugs dominate in India (NPR Health, March 9, 2018)
RTI replies reveal a deal between Janssen and MoH for Bedaquiline (SpicyIP, March 8, 2018)
India’s top selling diabetes drugs backed up by inadequate clinical data (The Wire, March 8, 2018)
New medical regulation rules in Karnataka suggest the government has flip-flopped (The Wire, March 8, 2018)
Ranbaxy-Daiichi dispute: Implications for buyers and sellers (Mondaq.com, March 8, 2018)
Special Report: The smoke and mirrors surrounding the approval of Bedaliquine (SpicyIP, March 6, 2018)
US FDA: a risk that keeps on giving (The Mint, March 6, 2018)
The smoke & mirrors around the approval of Bedaquiline (SpicyIP, March 6, 2018)
10 year jail, 3 lakh fine for selling substandard drugs (The Tribune, March 2, 2018)
Auditor raises red flags in Fortis Healthcare’s quarterly earnings report (The Week, March 1, 2018)
Fortis to launch probe into alleged siphoning of cash by Malvinder, Shivinder Singh (Zee Business, March 1, 2018)
Statutory auditor Deloitte raises several red flags in Fortis Q2 & Q3 earnings review (moneycontrol.com, March 1, 2018)
Fortis to hire external legal firm to probe promoters’ fund misappropriation (India Today, March 1, 2018)
Fortis Q2, Q3 earnings red-flagged by Deloitte (Business Today, March 1, 2018)
Compliance Recap: Data integrity threatens US $4.3 billion Frensius-Akron deal (Pharmacompass, March 1, 2018)
Indian court seizes former Ranbaxy owners’ assets (Chemistry World, March 1, 2018)
Fraud scandals washing over corporate India gives investors a pause (The Mint, February 28, 2018)
Is Fortis going the Satyam/Mallya way? (The Week, February 27, 2018)
Could Fortis become a repeat of Satyam Computer? (DNA, February, 27, 2018
Religare asks regulator to declassify Singh brothers as promoters (Bloomberg, February 20, 2018)
Business & fraud: inseperable twins? (Freepress journal, February 19, 2018)
SIFO to probe Fortis, Religare for alleged “loan” to Singh brothers (Business Today, February 19, 2018)
Lessons from Ranbaxy: Suffocating silence prevented us from questioning the rot in the system (The Wire, February 19, 2018)
Ranbaxy deal: SC dismisses Singh brothers’ appeal (Financial Express, February 17, 2018)
Supreme Court rejects Singh brothers’ plea against Delhi High Court Order (Bloomberg, February 16, 2018)
Ranbaxy case:SC rejects plea by Singh brothers against Daiichi Sankyo’s RS 3500 crore award (The Mint, February 16, 2018)
Singh brothers out of options to avoid Daiichi award as SC junks appeal (Business Standard, February 16, 2018)
SC dismisses Singh brothers’ appeal against Rs 3500 crore arbitral award to Daiichi (LiveLaw.in, February 16, 2018)
Is private healthcare really making losses: The Fortis Story (Times of India, February 15, 2018)
The Singh brothers are the reason the 1% cops the blame (The Mint, February 14, 2018)
Why the billionaire Singh brothers could be entering endgame phase (Business Standard, February 12, 2018)
India’s Singh brothers: How to make and break a fortune in ten years (Quartz, February 12, 2018)
Where the system works in India (Bloomberg, February 12, 2018)
Fortis healthcare governance comes under spotlight as promoters “take out” Rs 473 crore (Moneycontrol, February 10, 2018)
Singhs said to have taken Rs 500 crore from Fortis Healthcare (Mint, February 9, 2018)
Indian tycoons took $78 million out of hospital firm Fortis, sources say (Bloomberg, February 9, 2018)
Singh brothers took USD 78 million out of Fortis without Board Approval (Deccan Chronicle, February 9, 2018)
Malvinder & Shivinder Singh took Rs 5 billion out of Fortis without Board nod (Business Standard, February 9, 2018)
Fortis says Singh brothers agreed to repay Rs 473 crore diverted from the company (Moneycontrol, February 9, 2018)
The Ranbaxy Saga (Business Today, February 7, 2018)
Deadly drug cocktails in India (The Hindu, February 6, 2018)
How did the court arrive at 3500 crore damage award (Economic Times, February 5, 208)
Multinational companies continue to produce unregulated antibiotics in India (EurakAlert, February 4, 2018)
Delhi HC upholds arbitral award in favor of Daiichi-Sankyo, directs Ranbaxy Singh brothers to pay penalty of USD 500 million (The Indian Jurist, February 1, 2018)
HC upholds Daiichi’s Rs 3,500 crore arbitral award against Singh Brothers (Financial Express, January 31, 2018)
Daiichi wins $550 million award enforcement case in India (Bloomberg, January 31, 2018)
Comparison of drug prices in Us and in India (Pharmachemicalcoatings, January 19, 2018)
No clarity on probe into clinical trial violations (The Hindu, January 16, 2018)
Regulator weighs inspection of drug-making facilities in the US (Economic Times, January 16, 2018)
Plans to slash medical costs in America runs into generic drug concerns (Bloomberg, January 5, 2018)
Lured by blood money, serial volunteers set a disturbing trend (The Hindu, December 30, 2017)
Why the Indian Supreme Court’s judgment on combination drugs sends wrong signals (Scroll.in, December 29, 2017)
Lured by blood money: serial volunteers set a disturbing trend (The Hindu, December 20, 2017)
Drug Wars (Business Today, December 13, 2017)
When journalists swallow spin on substandard drugs (Newslaundry, December 12, 2017)
1 in 10 medicines in poor countries fake or substandard (Financial Express, December 1, 2017)
Drug Regulator to make “stability testing” a must for all medicines sold in India (The Mint, November 28, 2017)
US FDA delivers strong message to pharma companies on quality culture & data integrity (Business Today, November 21, 2017)
Banning combination drugs: A high stakes case in point (Indian Express, November 21, 2017)
India’s pharmaceutical prescription is unhealthy (Nikkei.com, November 12, 2017)
US generic drug pricing conspiracy jolts Indian pharma companies (Mint, November 3, 2017)
US may widen probe into 18 major Indian pharma firms (Indian Express, November 3, 2017)
SC disposes petition against Ranbaxy, directs CDSCO to take appropriate steps (Livelaw, Oct 28, 2017)
Reinspection of Divi’s Labs indicates a long haul ahead (Pharmacompass, September 26, 2017)
Indian pharma sector losing its sheen (Economic Times, September 20, 2017)
Stability testing: DCGI and Health Ministry must act together to ensure stable drugs (Indian Express, September 12, 2017)
Indian drug makers need to raise quality bar as US strengthens audits (LiveMint, September 4, 2017)
USFDA Observations: To improve report cards, comprehensive reforms must for domestic drug makers (The Indian Express, August 28, 2017)
Draft Pharmaceutical Policy 2017: Recognizing drug quality concerns in India signals a paradigm shift (The Indian Express, August 28, 2017)
Centre’s understanding of pharma industry wrong, not surprising draft policy is so flawed (Financial Express, August 18, 2017)
CPhI India finds two tier manufacturing market (pharmtech.com, August 18, 2017)
How innovative is the Indian pharmaceutical industry? (DNA India, August 10, 2017)
Health Ministry warns on rushed implementation of the generics plan (The Mint, August 8, 2017)
What ails the centre’s rx initiative? (The Hindu, August 4, 2017)
Are our prescription drugs really safe? (wkyc.com, July 25, 2017)
Indian drugs fail quality tests: Why the pills you pop are useless (catchnews.com, July 22, 2017)
Warning Letters and Indian Pharma (Biospectrum India, July 20, 2017)
Improving access to medicines: Simply going after big pharma is not helping anyone (The Newsminute, July 18, 2017)
Code to ban bribes to doctors in final stages (Times of India, July 15, 2017)
Making prescription of generic drugs mandatory and associated issues (The Hans India, July 12, 2017)
Is it the end of pharma dream run? (BusinessWorld, July 11, 2017)
Time to reinvent (Businessworld, July 11, 2017)
We’ve to be ready for scrutiny (Businessworld, July 11, 2017)
Looking for a quick cure (The Hindu, July 11, 2017)
Lupin sets off down Indian pharma industry’s long road to redemption (Reuters, July 9, 2017)
Poor quality drugs caused Niloufer maternal deaths- doctor’s panel (Times of India, July 8, 2017)
How India’s pharma growth fizzled out (Business Standard, July 5, 2017)
Problems at Pfizer’s US facility (pharmacompass, June 29, 2017)
2014 Bilaspur tubectomy deaths: Absconding pharma director held (Indian Express, June 29, 2017)
What you dont know about generic drugs and how it can hurt you (Bloomberg, June 26, 2017)
Government needs to stop speaking in different voices on FDC (The Hindu, June 23, 2017)
Is the FDA changing their interpretation? (FDAZilla, May 16, 2017)
Government’s cheap medicine scheme falls sick (Indian Express, June 25, 2017)
Fading glory: Indian pharma industry in uncharted terrain (livemint, June 23, 2017)
Pharma: Searching for recovery room (livemint, June 23, 2017)
US FDA plans to ease entry of generic drugs (livemint, June 23, 2017)
Clinical trials in India need better regulations (thewire.in, June 22, 2017)
Drug price control: Cheap medicines to cost a fortune (Financial Express, June 12, 2017)
Generic medicines: Some questions (The Star of Mysore, June 11, 2017)
India needs to be more transparent about disease threats (thewire.in, June 11, 2017)
Doctors and their devices (Outlook, June 9, 2017)
80% of the data in Chinese Trials has been fabricated (sciencealert.com, June 9, 2017)
WHO grants all-clear to Mylan’s India facility where US FDA had data integrity concerns (pharmacompass, June 7, 2017)
Drug control body orders “strong vigil” on Combiflam (Indian Express, June 5, 2017)
The debate around drug regulation should prioritize price and quality equally (thewire.in, June 4, 2017)
Generic drugs … the bottom line (Star of Mysore, June 2, 2017)
Delhi doctors defy central advisory on generic drugs (Sunday Guardian, May 28, 2017)
Rational Drug Policy needed to curb doctor-pharma nexus (Sunday Guardian, May 28, 2017)
Generic Drugs: The murkier side (Star of Mysore, May 27, 2017)
India is fighting at the WHO to make medicines cheaper, but drug quality is the real problem (thenewsminute.com, May 26, 2017)
Generic Vs Branded Medicine (Star of Mysore, May 18, 2017)
Why doctors want to sell to you that expensive medicine (Standard Digital, May 16, 2017)
Indian drugmaker stages worker strike to avoid FDA inspection (Biopharma, May 12, 2017)
India’s pharma industry is creating superbugs with its dirty effluent discharges (scroll.in, May 12, 2017)
The cure lies elsewhere (Indian Express, May 11, 2017)
Essential medicines list shouldnt be subject to price controls: Niti Ayog (Economic Times, May 10, 2017)
The world is looking for generic drugs – and India needs to keep delivering (The Wire, May 9, 2017)
Generic names: common cause, different solutions (The Hindu, May 9, 2017)
73 percent of doctors oppose push for generic drugs (Times of India, May 9, 2017)
US FDA warns Indian API maker for faking certificates of Analsyis (inPharma, May 03, 2017)
Doctors body fights for freedom on prescriptions, tells government to focus on price (Scroll.in, May 02, 2017)
Breathing new life into the Indian Healthcare System (Bureaucracy Today, May 01, 2017)
Govt arms lobby for pharma companies: Swadeshi Jagran Manch (Times of India, May 02, 2017)
Niti Ayog suggests delinking of National List of Essential Medicines and drug price control (Business Today, May 01, 2017)
Quality, not price is the key issue when prescribing generic drugs in India (thewire.in, May 01,2017)
Generic medicines in India: The myth and truth behind the healthcare issue (Firstpost, April 29, 2017)
Brand names can be added (The Telegraph, April 29, 2017)
Generic medicines Vs branded drugs: All you need to know about Modi government’s proposed law for affordable healthcare to all (New Nation, April 29, 2017)
Generic medicines Vs branded ones: What a common consumer must know (Smartcooky, April 29, 2017)
Generic or branded: The prescription must be rational (Medical Dialogues, April 29, 2017)
Why branded drugs cost so much more than their generic counterparts (Firstpost, April 29, 2017)
Generic medicines in a digital age (The Hindu, April 29, 2017)
Prescribing generics wont help unless pharmacists are regulated, say activists (The Hindu, April 28, 2017)
War On Generic Drugs Only Makes Drug Prices Higher (National Review, April 28, 2017)
Rims runs out of generic drug stocks (Times of India, April 28, 2017)
Doctors defy prescription code (The Telegraph, April 28, 2017)
Push to generic not to have much impact (ET Healthworld, April 25, 2017)
Most prescribed drugs at AIIMS not available at the store (The Hindu, April 25, 2017)
Government policy to push generic drugs will succeed if confidence in quality improves (ET Healthworld, April 25, 2017)
Generic drugs look good on paper only (Asian age, April 22, 2017)
“Generic” diktat to doctors raises queries (The Telegraph, April 22, 2017)
Healthcare for all: Not just PM’s call (Mumbai Mirror, April 22, 2017)
PM Modi’s proposal on generic drugs isnt a new one (Economic Times, April 22m 2017)
CDSCO finds D-Cold Total, Combiflam to be substandard (Indian Express, April 21, 2017)
Perception, quality concerns cloud push for generic drugs (Times of India, April 21, 2017)
Why generics may not really be the cure in India (Financial Express, April 20, 2017)
Generic prescription hurdles: Doctors cite safety concerns, describe move as impractical (The Telegraph, April 20, 2017)
PM’s push for generic drugs to shift focus to chemists: IPA (moneycontrol.com, April 19, 2017)
Right Prescription (Indian Express, April 19, 2017)
Spotlight on generic drugs (Hans India, April 19, 2017)
Doctors lukewarm on generic drug plan (The Hindu, April 19, 2017)
Generic drugs no show at private hospitals, doctors blame quality (Times of India, April 19, 2017)
Modi govt plan on generic drugs makes pharma companies, doctors jittery (Business Standard, April 19, 2017)
Generic drugs “need” quality check (Deccan Chronicle, April 19, 2017)
Enforcing generic drugs hints at a new public health framework (Economic Times, April 19, 2017)
Prescribing generic drugs only the first step, long way to go (The Hindu, April 19, 2017)
Retail margin on generic drugs may be as high as 1000%, claims study (Times of India, April 19, 2017)
Law on generic medicines a boon for public, but ensure quality first (Economic Times, April 18, 2017)
Experts oppose govt plan to bring law on generic drugs (The Week, April 18, 2017)
Pharmaceutical Industry: It is refreshing to see administration responding to its citizens (Indian Express, April 18, 2017)
It is time to check safety, not price, of imported drugs (realclearhealth.com, April 13, 2017)
India makes a long overdue move to ensure better drug safety (scroll.in, April 12, 2017)
Turf War (Business Today, April 23, 2017)
Cookery of clinical trials (The Hindu, April 9, 2017)
Deja Vu at the FDA (The Milbank Quarterly, April 2017)
Independent regulator sought for medical devices (Indian Express, April 9, 2017)
US FDA sounds alert on quality issues in Indian pharma (Business Standard, April 8, 2017)
IPA punches holes into drug pricing policy implementation (Economic Times, April 4, 2017)
Years after assurance, government yet to move on request to ban 37 “harmful drugs” (Indian Express, April 3, 2017)
Has the Indian pharmaceutical sector become a soft target? (moneycontrol.com, April 3, 2017)
Two pharma cos seek fresh WHO-GMP certification after the state FDA cancelled their licenses (pharmabiz.com, April 3, 2017)
Activists urge government to put strict regulations to oversee Indian drug manufacturing (Deccan Chronicle, March 28, 2017)
Divi’s inspection reveals FDA’s shifting focus beyond audit trails (Pharmacompass, 29 March, 2017)
EMA calls to suspend more than 300 drugs due to unreliable studies from Indian CRO (RAPS, March 24, 2017)
US bans Indian drugmaker Divi’s factory: shares hit 3 year low (Reuters, March 22, 2017)
A message for Indian pharma: Do what you say, say what you do (moneycontrol.com, March 21, 2017)
FDA warns Megafine over Data Integrity violations at second facility (RAPS, March 07, 2017)
Drugs sold in India are not of standard quality: US FDA (ET Healthworld, February 25, 2017)
Another US warning on Indian drugs (Business Standard, February 24, 2017)
Sub-standard medicines more than national average in Punjab: Survey (Hindustan Times, February 22, 2017)
Over 10 pc of drugs in govt supply chain substandard: survey (Outlook Magazine, February 22, 2017)
Cipla Global Quality Chief on data integrity violations: “Bosses pushing juniors need to be whacked” (Indian Express, February 14, 2017)
JK needs to tackle substandard drug menace: Central Drug Authority (Greater Kashmir, February 10, 2017)
Sub-standard drugs (Daily Excelsior, January 31, 2017)
Document shredding at night raises FDA eyebrows during India visit (Bloomberg, January 24, 2017)
Why India’s generic drug industry has a long way to go to gain US FDA trust (Live Mint, January 24, 2017)
US FDA notice to Hetero Drugs over conditions at Telangana Unit (The Economic Times, January 24, 2017)
Daiichi Sankyo says Ranbaxy founders Malvinder and Shivinder Singh misled court (The Economic Times, January 23, 2017)
2016 – A year of data integrity issues and pharma non-compliance (www.pharmacompass.com, January 19, 2017)
4-5 percent drugs sub-standard, need concerted effort and stern action (Indian Express, January 3, 2017)
Serial testers and cursory checks: India’s flawed generic drug trials business (The Times of India, December 27, 2016)
346 EU Medicines under review as data-integrity concerns emerge at another CRO in India (PharmaCompass, December 22, 2016)
Pharma industry’s playbook on low-quality drugs (Indian Express, December 20, 2016)
US FDA finds fault in accuracy of test methods at Sun’s Halol site (Economic Times, December 13, 2016)
US FDA found Testing, Reporting shortfall at Sun Pharma Plant (Bloomberg, December 12, 2016)
Mozambique raises quality concerns about Indian drug exports (Indian Express, December 12, 2016)
U.S. FDA Found Testing, Reporting Shortfalls at Sun Pharma Plant (Bloomberg, December 12, 2016)
India’s therapeutic jungle (Deccan Herald, December 11, 2016)
Its wait and watch for Indian pharma industry (Deccan Herald, December 11, 2016)
The Delhi High Court allows 344 potentially dangerous combination drugs to remain on the market (Scroll.in, December 8, 2016)
Pharma companies bat for settlement out of court on FDC issue (ET Healthworld, December 2, 2016)
How and why Delhi High Court revoked ban on 344 popular drugs (The Indian Express, December 2, 2016)
Delhi High Court sets aside center’s ban on 344 fixed dose combinations, terms it haphazard (The Economic Times, December 2, 2016)
Bitter Pills (Editorial, Indian Express, November 30, 2016)
Drug Regulation: 27 medicines sold by top firms “fail” quality tests in seven states (Indian Express, November 28, 2016)
Sun Pharma’s Mohali unit violated manufacturing norms, US FDA (Live Mint, November 25, 2016
US FDA issues seven observations on Sun Pharma’s Mohali Site (Economic Times, November 24, 2016)
39 Indian drug companies blacklisted by Vietnam (International Business Times, November 23, 2016)
Generics Vs Big Pharma, reloaded (The Hindu, November 23, 2016)
Spurious drugs imported from China raise red flags for pharma regulator (Economic Times, November 11, 2016)
Are Indian pharma firms breeding superbugs, and should it scare us all? (Economic Times, November 6,2016)
After India, EU to probe Wanbury Pharma for illegal exports (Economic Times, Oct 31, 2016)
Corruption and substandard medicine in Latin America (Realclearhealth, October 27, 2016)
Inquiry pins FDA officers in unauthorized distribution of codeine phosphate (Indian Express, October 25, 2016)
Wanbury export issue shows regulator miscommunication (Economic Times, October 25, 2016)
Wanbury under lens for illegal export of diabetes drug (Economic Times, October 24, 2016)
The Supreme Court of frivolous PILs:Why Indian judiciary must focus on important petitions (The NewsMinute, October 20, 2016)
How dirty production of NHS drugs helps create superbugs (The bureau of investigative journalism, October 18, 2016)
Deregulation in pharma industry at the time of scandals (The News Minute, October 17th, 2016)
Indian pharma firms caught for exporting counterfeit drugs, Securing Industry, October 12, 2016
Quality assurance departments are often given a low priority in the pharma industry (Business Today, October 10, 2016)
Fix India’s fragmented drug regulation (Economic Times Editorial, September 28, 2016)
Clinton foundation AIDS program distributed “watered down” drugs to third world countries (The Daily Caller, September 19, 2016)
India, China absent as countries align on global pharma quality standards (Pharma Compass, September 15, 2016)
FDA norms punch a 5 crore hole in the pharma industry (Economic Times, September 15, 2016)
Regulators step up scrutiny of drug makers (Business Standard, September 14, 2016)
Panel to investigate pharma firms red-listed by Vietnam (The Mint, September 4, 2016)
Are Indian drug regulators failing Indians? (The News Minute, September 6, 2016)
Indian government moves to tackle substandard drugs (The Pharma Letter, August 31, 2016)
Welspun fiasco shows Indian companies have a blind spot on quality (The Mint, August 31, 2016)
Substandard medicines: Health ministry study on quality looks odd (The Financial Express, August 23, 2016)
D aiichi case: Former Ranbaxy promotes object to enforcement of Singapore arbitration award in India (Business Standard, August 23, 2016)
Why did the Indian Express pull down its story on Ranbaxy (Newslaundry, August 19, 2016)
Indian drug makers brace for slow growth at home (The Mint, August 17, 2016)
What’s ailing the pharma sector? (Business Standard, August 17, 2016)
Newslaundry Hafta Podcast (newslaundry.com, August 12, 2016, starting 22 minutes into the podcast)
Should bury data, said Ranbaxy chief when R&D chief revealed fudge: Tribunal Order (The Indian Express, August 12, 2016) Newspaper Clippings: IE Ranbaxy Ruling II – page 1 & IE Ranbaxy Ruling II – page 2
Terrible … put patients at risk: Ranbaxy’s own expert Richard Cooper (The Indian Express, August 12, 2016) Newspaper Clippings: IE Ranbaxy Ruling I – page 1 & IE Ranbaxy Ruling I – page 4
Ranbaxy-Daiichi affair: How & why the deal went south (Business Standard, August 12, 2016)
Singapore tribunal reveals how Ranbaxy buried info on fraud, duped its owners (The Indian Express, August 11, 2016)
Pharmexcil swings into action to contain drop in pharma exports (ETHealthworld, August 11, 2016)
Easing clinical trial rules to compromise safety of subjects, say health activities (The Economic Times, August 10, 2016)
Meet India’s pharmaceutical whistleblower (Nikkei Asian Review, August 4, 2016)
India has a competent enough system to check quality standards – G N Singh (Business Today, July 31, 2016)
Why India desperately needs a public procurement policy for pharmaceuticals (Caravan Magazine, July 7, 2016)
USFDA nods to desi drugs up 84% in 1 year (ET HealthWorld, June 27, 2016)
Criminally prosecute manufacturers of substandard drugs (Navbharat Times, June 23, 2016)
India needs strict prosecution laws to fix drug regulatory system: Ranbaxy whistleblower Dinesh Thakur (Economic Times, June 24, 2016)
India to revise drug law, draft new rules for medical devices (Deccan Chronicle. June 23, 2016)
Cabinet withdraws drugs & cosmetics amendment bill (The Mint, June 22, 2016)
India to revise drug law, draft new rules for medical devices (Reuters, June 22, 2016)
Indian drug regulator tags 200 firms for inspection on poor manufacturing quality (Fierce Pharma, June 22, 2016)
India makes it easier to buy its generic drug makers, but will anyone bite? (Pharmalot, June 22, 2016)
Withdrawal of the Drugs and Cosmetics (Amendment) Bill, 2013 (Livelaw.in, June 22, 2016)
CIPMMA urges DCGI to provide prior information to industry about listing of drugs under ‘banned category’ (Pharmabiz.com, June 21, 2016)
Pharma biggies among 200 under lens for poor drugs (The Times of India, June 20, 2016)
M&A ka side effects (Express Pharma, June 20, 2016)
Two Indian Contract Pharma, API manufacturers refuse FDA Inspections (RAPS, June 16, 2016)
Union Health Ministry to give Drugs and Cosmetics Act a makeover (India Today, June 15, 2016)
CDSCO renews API firms’ ‘written confirmations’ days after industry raises trade concerns (in-pharmatechnologist.com, June 13, 2016)
India’s pharma markets dips to a 2-year low in May (Economic Times, June 10, 2016)
Drug Regulator finds Alkem Labs’ drug substandards, again (Business Standard, June 9, 2016)
Health Ministry begins work on new law for safer drugs (Economic Times, June 8, 2016)
FDC ban shows India in poor light: Commerce Ministry (Hindustan Times, June 2, 2016)
No remedy – India lacks an effective drug recall system (The Caravan, June 1, 2016)
Vacant posts cripple drug regulation (May 30, 2016, Deccan Herald)
AIDCOC objects CDSCO’s move to send inspection notice to cos without prior consultation of state drug controllers (Pharmabiz.com, May 24,2016)
CRISIL warns sharp decline in Indian pharma exports in next five years (May 18, 2016)
Six major companies found manufacturing “substandard” drugs (Business Standard, May 18, 2016)
How drug whistle-blowers in India have to fight a long battle (Economic Times, May 18, 2016)
Corporate lying and collateral damage (Mint, May 18, 2016)
Globalization of drug manufacturing raises concerns over quality (Financial Times, May 16, 2016)
MP government procures substandard drugs, alleges Digvijay, writes to PM Modi (Indian Express, May 11, 2016)
More trouble for Ranbaxy as central regulator finds deficiencies (CNBC TV18, May 9, 2016)
Ranbaxy-Daiichi Singh brothers case brings to fore issue of drug quality in India (Financial Express, May 9, 2016)
Financial Express Editorial: A Chronic Illness (Financial Express, May 9, 2016)
Drug regulatory structure not sound: Governance Now (May 6, 2016)
Daiichi’s soured dream and a $5.5 billion hole in the pocket (Business Today, May 6, 2016)
Former Ranbaxy owners ordered to pay Daiichi Sankyo $525 million (FiercePharma, May 5, 2016)
Bhupesh Bhandari: Listen to Dinesh Thakur (Business Standard, May 5, 2016)
Former Ranbaxy owners told to pay Rs 2500 Crore for misrepresenting facts in Daiichi sale (The Mint, May 5, 2016)
Former Ranbaxy promoters fined $400 million for hiding facts from Daiichi (Economic Times, May 5, 2016)
Indian drug units violate most US pharma regulators’ rules (Business Standard, May 5, 2016)
Pharma Whistleblower: Consumers must question medicine quality (CNBC TV18, April 29, 2016)
- YouTube Video Link
Fixing India’s drug quality problem (Economic Times, April 27, 2016)
How to avoid a bad trip (Economic Times, April 26, 2016)
Panic signals in India as USFDA asks drug companies to repeat Semler’s studies (Economic Times, April 25, 2016)
Semler gets WHO notice of concern over violation of ideal laboratory and clinical practices (Economic Times, April 25, 2016)
FDA finds another Indian CRO fudged clinical data (US FDA, April 20, 2016)
Indian drug regulation weakest in the world: need to bolster it (ET Healthworld, April 20, 2016)
Indian drug control weakest in the world, says top government official (April 20, 2016)
Impact of regulatory structure on public health in India (National Institute of Public Finance & Policy, April 19, 2016)
The real story behind drug approvals (The Hindu Business Line, April 19, 2016)
Indian drug firms struggle with quality issues (Chemical & Engineering News, April 18, 2016)
Data Integrity and cGMP Manufacturing: US FDA offers new draft guidance (RAPS, April 14, 2016)
Study on use of FDCs reveals lack of awareness of use (Pharmabiz, April 7, 2016)
F DC ban order was legislative exercise, government tells Delhi HC (The Mint, April 7, 2016)
How can DCGI approved drugs be banned: HC asks Government (Outlook, April 6, 2016)
How can govt ban a drug without cancelling license, asks high court (Financial Express, April 4, 2016)
Cleaning up the Pharma industry (Economic & Political Weekly, April 2, 2016)
Who will heal our drug industry? (The Hindu, April 1, 2016)
Govt banned FDCs without considering clinical data (Business Standard, March 29, 2016)
You have no power to control state drug authorities: HC to Govt (Outlook, March 28, 2016)
Govt speaks up on FDC Ban, tells Delhi HC banned drugs are unsafe (Bar & Bench, March 28, 2016)
HC slams government for banning drugs, says you have no power to control state authorities (DNA, March 28, 2016)
Indian pharma impeded by regulatory overlaps and lack of structure (The National, March 26, 2016)
Knee-jerk reaction (Business Standard, March 17, 2016)
Dinesh Thakur’s PIL highlights the well known challenges of India’s drug regulatory system (TwoFour Insights, March 14, 2016)
NDTV Panel on prevalence of Fixed Dose Combination drugs in India (NDTV, March 14, 2016)
Rip apart the current system (Business Today, March 13, 2016)
Supreme Court junks whistleblower’s plea against drug regulators (Financial Express, March 12, 2016)
Supreme Court gets tough on PILs (The Mint; March 11, 2016)
SC dismisses PILs by Ranbaxy whistleblower Dinesh Thakur (Business Standard, March 11, 2016)
India’s supreme court denies petitions challenging CDSCO (RAPS-Focus, March 11, 2016)
The rot in drug regulation (Business Standard; March 10, 2016)
Pharma whistleblower takes on India’s regulators (Pharmalot; March 9, 2016)
Whistleblower raises questions on DCGI, drug regulatory system (Economic Times; March 9, 2016)
Whistle-blower of unsafe medicines takes on “Make in India” (Bloomberg; March 8, 2016)
Lawsuits seek tighter regulation of India’s pharma industry (Financial Times; March 7, 2016)
Let them speak up (The Hindu Business Line, February 8, 2016)
India’s fake drug trials threaten wider trade deal (Newsweek, January 24, 2016)
How the Indian Government helped let GVK Biosciences off the hook (The Wire, December 20, 2015)
There is no romance in this story of fudged clinical trials (The Wire, December 19, 2015)
Maggi ban: Just another instance of Indian nationalism blinding us to real problems (Scroll.in, October 21, 2015)
The drugs don’t work: Indian reporters need to ask regulators tough questions on substandard medicines (Newslaundry.com, October 7, 2015)
A new class of drugs is here – but India is dangerously inept at dealing with them (Scroll.in, September 16, 2015)
Indian drugs: not what the doctor ordered (Financial Times, September 9, 2015)
Beware of ‘Made in India’ medicine (The Hindu Business Line, August 12, 2015)
Can FDA adequately police generic drugs? Agency says no (New Haven Register, July 13, 2015)
Not all generic drugs are created equal: Why FDA, NIH and Congress need to protect Americans (Fox News, March 19, 2015)
Worth the price? Push for cheaper generic drugs has Canadians buying questionable medicines from India (National Post, March 13, 2015)
FDA should follow Europe’s lead on Indian drug suspensions (The Hill, March 12, 2015)
EU regulator calls for generic drug suspensions (Chemistry World, February 2, 2015)
FDA Boosts Testing of Generic Drugs As Quality Concerns Mount (Healthline; Feb. 27, 2014)
Indian drug deficiencies cause furore in Canada (The Hindu, September 12, 2014)
Poor quality of TB drugs (Times of India, March 7, 2014)
India is harming itself by taking US drug safety concerns lightly (First Post; Feb. 27, 2014)
FDA Failed to Track Substandard Generics, Congress Told (Bloomberg; Feb. 27, 2014)
Made-in-India drugs to be in dock at Capitol Hill (Business Standard; Feb. 27, 2014)
Capitol hearing puts pressure on India to ramp up quality controls (in-Pharma; Feb. 27, 2014)
Substandard Generic Drugs Slip Past U.S. FDA Effort, Doctors Say (Bloomberg Businessweek; Feb. 27, 2014)
Ranbaxy Laboratories whistleblower: Downgrade pharma industry till India gets its act together (Financial Express; Feb. 27, 2014)
Ranbaxy whistleblower shares his experiences with US lawmakers (Economic Times; Feb. 27, 2014)
Some Indian Generic Drug Companies Are Selling Shoddy, Ineffective, FDA-Approved Medicines To U.S. Patients (Forbes; Feb. 24, 2014)
India’s drug quality under the spotlight with FDA head visit (Searching for Safety – Working Paper #06; Feb. 2014)
US “not targeting” India, says FDA chief (Channel News Asia; Feb. 22, 2014)
Generic-Drug Testing Goes Widespread in U.S. FDA Effort (Bloomberg; Feb. 22, 2014)
Generic Drugs Evaluated in First Broad Test Effort by U.S. FDA (Businessweek; Feb. 22, 2014)
FDA chief says U.S. not targeting Indian drug companies in crackdown (Reuters; Feb. 21, 2014)
The Safety Of Prescription Drugs Made Outside The U.S. (NPR — Diane Rehm Show; Feb. 20, 2014)
Ranbaxy’s empty promises (Fortune; Feb. 3, 2014)
Ranbaxy in need of further treatment (Financial Times; Feb. 2, 2014)
US troubles may haunt Ranbaxy elsewhere too (Business Standard; Jan. 30, 3014)
If I follow US standards, I will have to shut almost all drug facilities: G N Singh (Business Standard; Jan. 30, 2014)
Decoding the FDA’s Ranbaxy inspections (The Hindu; Jan. 29, 2014)
Indian pharma’s twin woes (Business Standard; Jan. 27, 2014)
Bitter medicine (Business Line – The Hindu; Jan. 27, 2014)
Dual standards not acceptable: Indian regulator to Ranbaxy (Business Line – The Hindu; Jan. 27, 2014)
Doctor’s body to seek regulator’s view on quality of Ranbaxy drugs (The Economic Times; Jan. 27, 2014)
Are Indian pharma companies overdosing on lethal drug of fraud? (The Economic Times; Jan. 27, 2014)
‘Our propensity for jugaad comes in the way of developing quality’ (Business Line – The Hindu; Jan. 26, 2014)
No relief for Ranbaxy in the near term (Economic Times; Jan. 24, 2004)
India’s Ranbaxy hit by FDA product ban at 4th Indian plant (Reuters; Jan. 24, 2014)
Daiichi says new API import ban will effect Ranbaxy’s US ops (in-Pharma; Jan. 23, 2014)
British regulator warns Indian drug companies after data scandal (The Telegraph; Dec. 30, 2013)
China Drugmakers Face U.S. Scrutiny on Investigator Bump (Bloomberg; Dec. 10, 2013)
U.S. doctor questions effectiveness of Ranbaxy drugs (The Hindu; Dec. 6, 2013)
Mass movement needed for better governance (Business Line – The Hindu; Dec. 5, 2013)
‘Pharma industry has a deep culture of corruption’ (The Hindu; Dec. 3, 2013)
Dangerous drugs in your medicine cabinet? A whistleblower’s account of India’s troubling exports (AEI; Dec. 2, 2013)
‘Ask your doctor about a drug’s side-effects’ (Times of India; Nov. 23, 2013)
Himachal drug hub gone rouge (Hill Post; Nov. 21, 2013)
Ranbaxy whistleblower Dinesh Thakur wants strong policy to unearth fraud (The Economic Times; Nov. 21, 2013)
India’s Dangerous Drug Problem (International Business Times: Nov. 19, 2013)
Ranbaxy is like a big ship, you can’t change its direction overnight: Dinesh Thakur (Business Standard; Nov. 19, 2013)
Questions about India’s drug industry (The Hindu; Nov. 15, 2013)
Malvinder Singh under cloud over Ranbaxy imbroglio (The Hindu; Nov. 9, 2013)
Former employee approached generic drug maker with fraud suspicions (CBS Evening News; Nov. 6, 2013)
Doctor: $500M Ranbaxy fine simply “cost of doing business (CBS Evening News; Nov. 6, 2013)
Ranbaxy whistleblower reveals how he exposed massive pharmaceutical fraud (CBS This Morning; Nov. 6, 2013)
Leading generic drug maker faked test results for FDA approval (CBS Evening News; Nov. 5, 2013)
Generic drug maker skipped steps required for FDA approval (CBS Evening News; Nov. 5, 2013)
Ranbaxy whistleblower honoured (The Hindu; Oct. 26, 2013)
Ranbaxy’s chronic maladies (The Economist; Sept. 21, 2013)
Another bitter pill for Ranbaxy, now US plant under FDA lens (Business Standard; Sept. 20, 2013)
No major violations at Ranbaxy’s Mohali plant: India’s drug regulator (Mint/WSJ; Sept. 19, 2013)
Ranbaxy import ban: USFDA found suspected hair, oil in tablets (Business Standard; Sept. 18, 2013)
FDA finds quality, process lapses at Ranbaxy plant (Business Line – The Hindu; Sept. 18, 2013)
FDA uncovers big foul-ups at Ranbaxy plant (FiercePharma; Sept. 18, 2013)
Ranbaxy import ban: USFDA found suspected hair, oil in tablets (Economic Times; Sept. 18, 2013)
India’s drug regulator asleep on the job? (Economic Times; Sept. 18, 2013)
Ranbaxy’s woes far from over (Business Line – The Hindu; Sept. 17, 2013)
Ranbaxy in a spot; investors losing faith? (Money Control; Sept. 17, 2013)
Ranbaxy drops a staggering 29.98% on USFDA alert (Business Standard; Sept. 16, 2013)
India’s NSE index falls; Ranbaxy plummets after third FDA ban (Reuters; Sept. 16, 2013)
Explainer: Five reasons why Ranbaxy crashed 30 percent (FirstPost; Sept. 16, 2013)
Indian drugmaker Ranbaxy faces new US regulation woes (Economic Times; Sept. 16, 2013)
Ranbaxy slips 30% on fresh US FDA warning. Avoid, say analysts (Business Standard; Sept. 16, 2013)
Ranbaxy’s Mohali plant under USFDA lens (The Hindu; Sept. 16, 2013)
Third FDA ban on India’s Ranbaxy threatens its U.S. sales (Reuters; Sept. 15, 2013)
Daiichi Sankyo attempts to restore Ranbaxy’s credibility, but difficult road ahead (Economic Times; Aug. 4, 2013)
Corruption: MNCs can’t pass the buck (Business Line; Aug. 4, 2013)
FDA’s letter to Wockhardt is fair (Mint/WSJ; Aug. 1, 2013)
Say no to jugaad (Business Standard; Aug. 1, 2013)
Ranbaxy’s Toansa, Mohali plants under US FDA scanner for manufacturing practices (Economic Times; July 17, 2013)
A Generic Doubt (Outlook; July 12, 2013/July 22, 2013 – Edition)
A blame game conundrum over Ranbaxy (Reuters; July 9, 2013)
Widespread retrenchment at Ranbaxy: 400 may be shown the door as it turns a house of trouble (Economic Times; July 6, 2013)
Can Ranbaxy come out of the shadows? (Business Standard; July 4, 2013)
‘The USFDA will increase its activities in India’ (Business Today; July 3, 2013)
US FDA inspections in India to increase (Money Control; July 2, 1013)
Corp governance rule to get stiffer for firms (Financial Chronicle; June 30, 2013)
After Ranbaxy, Wockhardt episodes must for drug cos to disclose global regulators’ action (The Economic Times; July 1, 2013)
India falling prey to sub-standard products? (Cool Age; June 28, 2013)
Guest column : The Ranbaxy fraud has revived the “counterfeits” debate. It shouldn’t. (Apothecurry; June 28, 2013)
Protect whistleblowers, but also pay them (Business Line: June 27, 2013)
Case asking for ban on Ranbaxy drugs in India in Supreme Court today (NDTV; June 25, 2013)
Now, Ranbaxy’s Mohali unit under FDA cloud (dna; June 25, 2013)
Ranbaxy deals with issues at Mohali plant (FiercePharma; June 25, 2013)
No trouble for Mohali unit, claims Ranbaxy; but what about governance? (FirstPost; June 25, 2013)
Now, Ranbaxy’s Mohali unit under FDA cloud (dna; June 25, 2013)
Mohali plant not in trouble: Ranbaxy (Times of India; June 25, 2013)
Ranbaxy reportedly has FDA issues at Mohali (FiercePharma;June 24, 2013)
Ranbaxy slumps on Mohali plant under USFDA watch reports (Money Control; June 24, 2013)
Pill of indictment (The Week; June 24, 2013)
UPDATED: Reported Form 483 may explain Ranbaxy not getting Diovan to market (FiercePharma; June 24, 2013)
Ranbaxy stock in free fall on uncertainty (Business Standard; June 24, 2013)
Ranbaxy reportedly has FDA issues at MohaliRanbaxy reportedly has FDA issues at Mohali (FiercePharma; June 24, 2013)
More trouble for Ranbaxy; Mohali unit may also have come under USFDA lens (Business Standard; June 24, 2013)
Ranbaxy: Growing uncertainties lead to a free fall (Business Standard; June 24, 2013)
Ranbaxy hits 52-week low on USFDA query on Mohali plant (Economic Times; June 24, 2013)
Ranbaxy Fines: More Than Meets The Eye (Asian Scientist; June 23, 2013)
Independent directors are answerable to stakeholders (Business Standard; June 23, 2013)
Are drugs mere placebos? (Business Line — The Hindu; June 23, 2013)
Indian drug makers face heat of US regulator’s crackdown (Business Standard; June 22, 2013)
Bad medicine ( Indian Express; June 21, 2013)
‘Adulteration’ defined differently in US and India: Ranbaxy (Money Control; June 19, 2013)
Lessons from the Ranbaxy fallout (Business Line — The Hindu; June 18, 2013)
Drug controller to fortify whistle blower scheme (Indian Express; June 17, 2013)
Project revital (Business Today; June 16, 2013/June 23, 2013 – Edition)
Who Manufactures Dirty Medicines? (News Click; June 15, 2013)
Is Pharma Excommunication Discouraging Potential Whistleblowers? (in-Pharma; June 13, 2013)
Past shortcomings rectified, regulators can check: Ranbaxy (Deccan Herald; June 13, 2013)
The unhealthy legacy of process patents (Business Standard; June 13, 2013)
Britain ignored warnings of Indian whistleblower at heart of drugs scandal (Telegraph; June 13, 2013)
Setting things right, not aware of DCGI probe: Ranbaxy (Money Control; June 12, 2013)
Katherine Eban; Generic Drug Investigative Reporter On Generic Drug Production Corruption (OpEd News; June 12, 2013)
We trust indian manufacturing norms: USFDA (Economic Times; June 13, 2013)
The Indian way? No way (The Hindu; June 12, 2013)
SC ‘very serious’ tag on Ranbaxy charges (The Telegraph; June 11, 2013)
India taking closer look at Ranbaxy’s U.S. problems (FiercePharma Manufacturing; June, 10, 2013)
Ranbaxy drugs cleared FDA test before import alert (Business Standard; June 11, 2013)
Ranbaxy has erred, but it’s not the only one (Business Line — The Hindu; June 10, 2013)
Trouble in India for Ranbaxy after $500 million U.S. Penalty (Knowledge @ Wharton Today; June 10, 2013)
Corporate governance failure at Ranbaxy? (Business Standard; June 9, 2013)
Ranbaxy’s Dewas and Paonta units under DCGI scanner, to face inspection (Economic Times; June 10, 2013)
Ranbaxy issue a wake up call for pharma industry: Biocon chief (Financial Express; June 9, 2013)
Hospitals awaiting regulator’s guidance over Ranbaxy drugs (Financial Express; June 9, 2013)
More pain for Japan’s Daiichi hit by Ranbaxy fraud (Hindustan Times; June 9, 2013)
Corporate governance failure at Ranbaxy? (Business Standard; June 9, 2013)
Ranbaxy drugs: Apollo Pharmacy issues advisory (Times of India; June 8, 2013)
India’s largest pharmacy group halts sales of Ranbaxy drugs (FiercePharma; June 7, 2013)
Apollo Pharmacy halts sale of Ranbaxy drugs (Business Standard; June 7, 2013)
Ranbaxy spurious drugs update: DCGI probe will take a month, Apollo suspends sales ( Health.India.com; June 7, 2013)
Is the pharma industry adulterating drugs? (Face The Nation; June 6, 2013)
Filthy Pharma: Justice Department Taking “Especially Hard Look” At Manufacturing Plants (Forbes; June 6, 2013)
Indian litigation seeks to close Ranbaxy plants (Fierce Pharma Manufacturing; June 6, 2013)
FTN: Is the pharma industry adulterating drugs? (IBN; June 5, 2013)
Ranbaxy: Fall of an icon (Business Line — The Hindu; June 6, 2013)
Ranbaxy case: Should Indian patients worry over sub-standard drugs? (IBN Live; June 5, 2013)
Ranbaxy’s directors did not hear the whistle (Business Standard; June 5, 2013)
Ranbaxy under fire: Will India’s pharma industry be hit? (NDTV; June 4, 2013)
How can Daiichi fix the Ranbaxy mess? (Mint; June 4, 2013)
FDA has learnt from the Ranbaxy Case: Dinesh S. Thakur (Business Today; June, 4 2013/ June 23, 2013 – Edition)
Do Generic Drugs Make The Cut? (HuffPost Live; June 3, 2013)
An epidemic of cheating (Mint; June 2, 2013)
Follow US model to fight corporate corruption (New Indian Express; June, 3 2013)
How safe are medicines of Ranabaxy in India? (ABP News special; May 31, 2013)
US drug regulator detects lapses in Hospira’s TN unit (Times of India; May 31, 2013)
The loneliness of dissent (Mint; May 31, 2013)
Ranbaxy’s failure: Who, what and when? (Economic Times; May 31, 2013)
The landscapes of ethics (The Asian Age; May 30, 2013)
DC debate: Generic drugs — boon or bane (Deccan Chronicle; May 30, 2013)
Tarnished image (Deccan Herald; May 30, 2013)
रैनबैक्सी की कारगुजारी से उठे गंभीर सवाल (Naya India; May 30, 2013)
US Congress member Steve Israel seeks review of FDA’s Ranbaxy probe (Economic Times; May 30, 2013)
IPL Over Fake Drugs (News Laundry; May 30, 2013)
Ranbaxy Faces Quality Test By India Government Body (International Business Times; May 29, 2013)
FDA under fire over Ranbaxy imbroglio (The Hindu; May 29, 2013)
Ranbaxy matter sparks backlash years after first being uncovered (Fierce Pharma; May 29, 2013)
Ranbaxy got FDA raps on US facilities under Daiichi, too (Business Standard; May 29, 2013)
Rep. Israel: Generic Drug Supply Needs Better Oversight (CBS New York; May 28, 2013)
Drugs, Ranbaxy and lies (The Hindu; May 28, 2013)
Indian pharma’s generic challenge (Business Standard; May 28, 2013)
Indian pharma must turn proactive and consider a self-regulatory body (Economic Times; May 28, 2013)
Ranbaxy sold new drugs without nod, says USFDA plaint (Financial Express; May 28, 2013)
Ranbaxy ignored consultants’ warnings about US FDA action over malpractices, data manipulation (The Times of India; May 28, 2013)
Ranbaxy ignored consultants’ warnings about US FDA action over malpractices, data manipulation (The Economic Times; May 28, 2013)
Ranbaxy holds up an ugly mirror to corporate India (Mint; May 26, 2013)
Three idiots and a scam that won’t die (Times of India; May 26, 2013)
A deception most foul (The Hindu; May 26, 2013)
Clean As A Whistle (Outlook; May 25, 2013/June 3, 2013 — Magazine Issue)
Under Whose Watch Did The Ranbaxy Fraud Happen (Forbes; May 25, 2013)
One honest man was all it took to expose Ranbaxy’s colossal fraud (Daily Bhaskar; May 25, 2013)
FDA import alert may lead to $100-mn loss for Wockhardt (Business Standard; May 24, 2013)
A country for scandal? (Business Standard; May 24, 2013)
Ranbaxy a wake-up call for Indian pharma (Business Standard; May 24, 2013)
Ranbaxy settlement reflects growing scrutiny of drug manufacturing (Reuters; May 24, 2013)
Rush to quickly launch products & get US nod led Ranbaxy to fudging, says company former-execs (Economic Times; May 23, 2013)
Ranbaxy-Daiichi: The gloves are off (Business Today; May 23, 2013)
Cannot comment on charges against Ranbaxy: Thakur (CNBC; May 23, 2013)
Ranbaxy’s dark chapter (Business Standard; May 23, 2013)
The latest to claim fraud at generic Lipitor maker Ranbaxy: Its owners (Fortune; May 23, 2013)
Collateral damage: Ranbaxy fiasco may hit India’s image as cheap generic maker (Business Standard; May 23, 2013)
It’s not just Ranbaxy, our health care regulators have failed us too (Forbes; May 23, 2013)
Ranbaxy under India’s drug regulator scanner (Mint; May 23, 2013)
Will Ranbaxy’s shenanigans hurt Indian pharma? (dna; May 23, 2013)
Will Ranbaxy Labs Be Excluded From Medicare And Medicaid? (Forbes; May 22, 2013)
The surprising silence on corporate corruption (dna; May 22, 2013)
Daiichi may initiate legal action against former Ranbaxy shareholders (Mint; May 22, 2013)
Japan’s Daiichi says key details ‘concealed’ in Ranbaxy sale (AFP; May 22, 2013)
L’affaire Ranbaxy: Why is nobody bothered about Indians’ safety? (Firstpost; May 22, 2013)
Ranbaxy has taken steps to ensure quality control: Sawhney (Business Standard; May 22, 2013)
Ranbaxy episode to hit drugs carrying ‘India’ label; tough to secure new contracts (Economic Times; May 22, 2013)
Drug regulator to probe Ranbaxy records, approvals in India (Business Standard; May 21, 2013)
Ranbaxy Whistleblower: So Many Infractions And Each Was Egregious (Pharmalot; May 21, 2013)
Ranbaxy, FDA, FDASIA and Indian Pharma Credibility (RxTrace; May 20, 2013)
Wind Behind Their Back (Times of India; May 18, 2013)
The worst corporate scandal you never heard of (Global Dashboard; May 17, 2013)
Those Generic Drugs May Not Have Been What You Thought They Were (The Daily Beast; May 17, 2013)
Why whistle blowing is so hard in India (Forbes; May 17, 2013)
Help corporate whistleblowers (Mint; May 16, 2013)
Recovering a reputation: Ranbaxy needs to investigate internal wrongdoing (Business Standard; May 16, 2013)
Whistleblower: Ranbaxy systemically violated good manufacturing practices (The Indian Express; May 15, 2013)
FDA Fails to Catch Generic Drug Disasters (The People’s Pharmacy; May 15, 2013)
Ranbaxy ‘systematically violated’ good manufacturing practices: Whistleblower (Economic Times; May 14, 2013)
Generic Roulette (Medical Progress Today; May 13, 2013)
Ranbaxy Pays $500M To Settle Long-Running Production Scandal (Pharmalot; May 13, 2013)
Drug manufacturer Ranbaxy USA Inc. agrees to $500 million penalty (AP; May 13, 2013)
Generic Drug Maker Pleads Guilty in Federal Case (New York Times; May 13, 2013
Ranbaxy pleads guilty, to pay $500 million in U.S. settlement (Reuters; May 13, 2013)